Is there a canon for Young Adult literature? Helen Sykes IFTE Conference Auckland 2011.
S C HR IFTE NV E R Z E IC HNIS -...
21
SCHRIFTENVERZEICHNIS WINFRIED MÄRZ ORIGINALARBEITEN IN ZEITSCHRIFTEN MIT PEER REVIEW 1. März, W., Groß, W.: Separation of apolipoproteins of human very low density lipoproteins by chromatofocusing. J. Clin. Chem. Clin. Biochem. 21, 459-462, 1983 2. März, W., Groß, W.: Quantification of human serum lipoprotein Lp(a): zone immunoelectrophoresis assay, a new sensitive method as compared to electroimmuno assay. Clin. Chim. Acta 134, 265-279, 1983 3. Groß, W., März, W., Ohlenschläger, G.: Quantifizierung von Apolipoprotein C-III im Serum mittels Zonenimmunoassay. GIT Lab.-Med. 6, 376-378, 1983 4. Groß, W., März, W.: Bestimmung von Apolipoprotein C-II im menschlichen Serum mittels einer neuen immunologischen Methode, dem Zonenimmunoassay. GIT Lab. Med. 7, 200-205, 1984 5. März, W., Groß, W., Gahn, G., Romberg, G., Taubert, H.D., Kuhl, H.: A randomized crossover comparison of two low-dose contraceptives: effects on serum lipids and lipoproteins. Am. J. Obstet. Gynecol. 153, 287-293, 1985 6. Kuhl, H., Gahn, G., Romberg, G., März, W., Taubert, H.D.: A randomized cross-over comparison of two low- dose oral contraceptives upon hormonal and metabolic parameters. I. Effects upon sexual hormone levels. Contraception 31, 583-593, 1985 7. Groß, W., März, W.: Evaluation of an electroimmunoassay for the simultaneous determination of apolipoproteins A-I and B in human sera. Ärztl. Lab. 32, 143-153, 1985 8. März, W., Groß, W.: Analysis of plasma lipoproteins by ultracentrifugation in a new fixed angle rotor: evaluation of a phosphotungstic acid/MgCl 2 precipitation and a quantitative lipoprotein electrophoresis assay. Clin. Chim. Acta 160, 1-18, 1986 9. Groß, W., März, W.: Effect of free edetate on the determination of choline containing phospholipids. Ärztl. Lab. 33, 1-4, 1987 (Durchführung der Experimente, maMitarbeit am Manuskript) 10. März, W., Schenk, G., Groß, W.: Apolipoproteins C-II and C-III in serum quantified by zone immunoelectrophoresis. Clin. Chem. 33, 664-669, 1987 11. Jung-Hoffmann, C., März, W., Heidt, F., Groß, W., Kuhl, H.: Der Effekt zweier niedrigdosierter, Gestoden oder Desogestrel enthaltender Ovulationshemmer auf die Sexualhormone und den Fettstoffwechsel. Geburtsh. u. Frauenheilk. 48, 215-219, 1988 12. Grützmacher, P., März, W., Peschke, B., Groß, W., Schoeppe, W.: Lipoproteins and apolipoproteins during the progression of chronic renal desease. Nephron 50, 103-111, 1988 13. März, W., Groß, W.: Immunochemical evidence for the presence in human plasma of lipoproteins with apolipoprotein A-II as the major protein constituent. Biochim. Biophys. Acta 962, 155-158, 1988 14. März, W., Trommlitz, M., Groß, W.: Differential turbidimetric assay for subpopulations of lipoproteins containing apolipoprotein A-I. J. Clin. Chem. Clin. Biochem. 26, 573-578, 1988 15. März, W., Groß, W.: Ultracentrifugal determination of high-density lipoprotein subfractions HDL2 and HDL3 in a high capacity fixed angle rotor. Ärztl. Lab. 34, 265-270, 1988 16. Siekmeier, R., März, W., Groß, W.: Precipitation of LDL with sulfated polyanions: three methods compared. Clin. Chim. Acta 177, 221-230, 1988 (Konzeption der Studie, statistische Auswertung, Erstellung des Manuskripts) 17. März, W., Jung-Hoffmann, C., Heidt, F., Groß, W., Kuhl, H.: Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 µg ethinylestradiol and 75 µg gestodene or 150 µg desogestrel. Contraception 41, 245-258, 1990 18. Kuhl, H., März, W., Jung-Hoffmann, C., Heidt, F., Groß, W.: Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives. Am. J. Obstet. Gynecol. 163, 363-369, 1990 (Durchführung der Lipoproteinmessungen mit Hilfe technischen Personals, statistische Auswertung)
Transcript of S C HR IFTE NV E R Z E IC HNIS -...
S C H R I F T E N V E R Z E I C H N I S
W I N F R I E D M Ä R Z
ORIGINALARBEITEN IN ZEITSCHRIFTEN MIT PEER REVIEW 1. März, W., Groß, W.: Separation of apolipoproteins of human very low density lipoproteins by
chromatofocusing. J. Clin. Chem. Clin. Biochem. 21, 459-462, 1983
2. März, W., Groß, W.: Quantification of human serum lipoprotein Lp(a): zone immunoelectrophoresis assay, a new sensitive method as compared to electroimmuno assay. Clin. Chim. Acta 134, 265-279, 1983
3. Groß, W., März, W., Ohlenschläger, G.: Quantifizierung von Apolipoprotein C-III im Serum mittels Zonenimmunoassay. GIT Lab.-Med. 6, 376-378, 1983
4. Groß, W., März, W.: Bestimmung von Apolipoprotein C-II im menschlichen Serum mittels einer neuen immunologischen Methode, dem Zonenimmunoassay. GIT Lab. Med. 7, 200-205, 1984
5. März, W., Groß, W., Gahn, G., Romberg, G., Taubert, H.D., Kuhl, H.: A randomized crossover comparison of two low-dose contraceptives: effects on serum lipids and lipoproteins. Am. J. Obstet. Gynecol. 153, 287-293, 1985
6. Kuhl, H., Gahn, G., Romberg, G., März, W., Taubert, H.D.: A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters. I. Effects upon sexual hormone levels. Contraception 31, 583-593, 1985
7. Groß, W., März, W.: Evaluation of an electroimmunoassay for the simultaneous determination of apolipoproteins A-I and B in human sera. Ärztl. Lab. 32, 143-153, 1985
8. März, W., Groß, W.: Analysis of plasma lipoproteins by ultracentrifugation in a new fixed angle rotor: evaluation of a phosphotungstic acid/MgCl2 precipitation and a quantitative lipoprotein electrophoresis assay. Clin. Chim. Acta 160, 1-18, 1986
9. Groß, W., März, W.: Effect of free edetate on the determination of choline containing phospholipids. Ärztl. Lab. 33, 1-4, 1987 (Durchführung der Experimente, maMitarbeit am Manuskript)
10. März, W., Schenk, G., Groß, W.: Apolipoproteins C-II and C-III in serum quantified by zone immunoelectrophoresis. Clin. Chem. 33, 664-669, 1987
11. Jung-Hoffmann, C., März, W., Heidt, F., Groß, W., Kuhl, H.: Der Effekt zweier niedrigdosierter, Gestoden oder Desogestrel enthaltender Ovulationshemmer auf die Sexualhormone und den Fettstoffwechsel. Geburtsh. u. Frauenheilk. 48, 215-219, 1988
12. Grützmacher, P., März, W., Peschke, B., Groß, W., Schoeppe, W.: Lipoproteins and apolipoproteins during the progression of chronic renal desease. Nephron 50, 103-111, 1988
13. März, W., Groß, W.: Immunochemical evidence for the presence in human plasma of lipoproteins with apolipoprotein A-II as the major protein constituent. Biochim. Biophys. Acta 962, 155-158, 1988
14. März, W., Trommlitz, M., Groß, W.: Differential turbidimetric assay for subpopulations of lipoproteins containing apolipoprotein A-I. J. Clin. Chem. Clin. Biochem. 26, 573-578, 1988
15. März, W., Groß, W.: Ultracentrifugal determination of high-density lipoprotein subfractions HDL2 and HDL3 in a high capacity fixed angle rotor. Ärztl. Lab. 34, 265-270, 1988
16. Siekmeier, R., März, W., Groß, W.: Precipitation of LDL with sulfated polyanions: three methods compared. Clin. Chim. Acta 177, 221-230, 1988 (Konzeption der Studie, statistische Auswertung, Erstellung des Manuskripts)
17. März, W., Jung-Hoffmann, C., Heidt, F., Groß, W., Kuhl, H.: Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 µg ethinylestradiol and 75 µg gestodene or 150 µg desogestrel. Contraception 41, 245-258, 1990
18. Kuhl, H., März, W., Jung-Hoffmann, C., Heidt, F., Groß, W.: Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives. Am. J. Obstet. Gynecol. 163, 363-369, 1990 (Durchführung der Lipoproteinmessungen mit Hilfe technischen Personals, statistische Auswertung)
19. Siekmeier, R., März, W., Groß, W.: Insufficient accuracy and specificity of polyanion precipitation methods for quantifying low-density lipoproteins. Clin. Chem. 36, 2109-2113, 1990 (Konzeption der Studie, statistische Auswertung, Erstellung des Manuskripts)
20. Löw-Friedrich, I., Grützmacher, P., März, W., Bergmann, M., Schoeppe, W.: Long-term echocardiographic examinations in chronic hemodialysis patients substituted with recombinant human erythropoietin. Blood Purif. 8, 272-278, 1990 (Dokumentation, statistische Auswertung)
21. Löw-Friedrich, I., Grützmacher, P., März, W., Bergmann, M., Schoeppe, W.: Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am. J. Nephrol. 11, 54-60, 1991
22. März, W., Cezanne, S., Groß, W.: Phenotyping of apolipoprotein E by immunoblotting in immobilized pH gradients. Electrophoresis 12, 59-63, 1991
23. Hasibeder, H., Staab, H.J., Seibel, K., Heibel, B., Schmidle, G., März, W.: Clinical pharmacology of the hypocholesterolemic agent K 12.148 (Lifibrol) in healthy volunteers. Eur. J. Clin. Pharmacol. 40 (Suppl. 1) S91-S94, 1991
24. März, W., Trommlitz, M., Scharrer, I., Groß, W.: Apolipoprotein (a) concentrations are not related to the risk of venous thrombosis. Blood Coagulation and Fibrinolysis 2, 595-599, 1991
25. Regeniter, A., Seiffert, U.B., Siede, W.H., März, W., Unkelbach, U., Rübsamen-Waigmann, H., Brede H.D.: HIV-induzierte Hypocholesterinämie. Münch. Med. Wschr. 133, 696-699, 1991
26. Peschke, B., März, W., Kachel, H.G., Grützmacher, P., Schoeppe, W., Scheuermann, E.H.: Intraindividuelle Serum Lipid Profile vor und nach Nierentransplantation. Zeitschrift für Transplantationsmedizin 3, 181-184, 1991
27. Müller, H.M., Diekstall, F.F., Schmidt, E., März, W., Canzler, H., Demeler, U.: Lipoprotein (a): a risk factor for retinal vascular occlusion. German J. Ophthalmol. 1, 338-341, 1992
28. Ruzicka, V., März, W., Russ, A., Groß, W.: Apolipoprotein B (Arg3500→Gln) allele specific polymeras chane reaction: large-scale screening of pooled blood samples. J. Lipid Res. 33, 1563-1567, 1992
29. Russ, A.P., Ruzicka, V., März, W., Appelhans, H., Groß, W.: Amplification and direct sequencing of a cDNA encoding human cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase. Biochim. Biophys. Acta 1132, 329-331, 1992
30. März, W., Ruzicka, V., Pohl, T., Usadel, K.H., Groß, W.: Familial defective apolipoprotein B-100: mild hypercholesterolaemia without atherosclerosis in a homozygous patient. Lancet 340, 1362, 1992 (Letter)
31. März, W., Peschke, B., Ruzicka, V., Siekmeier, R., Groß, W., Schoeppe, W., Scheuermann, E.: Type III hyperlipoproteinemia acquired by liver transplantation. Transplantation 55, 284-288, 1993
32. März, W., Ruzicka, V., Fisher, E., Russ, A.P., Schneider, W., Groß, W.: Typing of the 3' hypervariable region of the apolipoprotein B gene: approaches, pitfalls, and applications. Electrophoresis 14, 169-173, 1993
33. März, W., Siekmeier, R., Groß, E., Groß, W.: Determination of lipoprotein(a): enzyme immunoassay and immunoradiometric assay compared. Clin. Chim. Acta 214, 153-163, 1993
34. Chen, M., März, W., Manfras, B.J., Kühnl, P., Usadel, K.H., Böhm, B.O.: Rapid and simple subtyping of the HLA-DRB3 gene in Graves' disease using temperature-gradient gel electrophoresis. Hum. Immunol. 36, 199-203, 1993 (Mitarbeit an der Methodenentwicklung und am Manuskript)
35. März, W., Siekmeier, R., Scharnagl, H., Seiffert, U.B., Groß, W.: Fast lipoprotein chromatography: new method of analysis for plasma lipoproteins. Clin. Chem. 39, 2276-2281, 1993
36. März, W., Siekmeier, R., Groß, W., Kostner, G.M.: Determination of Lipoprotein(a): evaluation of three methods. Eur. J. Clin. Chem. Clin. Biochem. 31, 295-301, 1993
37. Ruzicka, V., März, W., Russ, A., Groß, W.: Immuno-PCR with a commercially available avidin system. Science 260, 698-699, 1993 (Konzept der Studie, Mitarbeit am Manuskript)
38. März, W., Feussner, G., Siekmeier, R., Donnerhak, B., Schaaf, L., Ruzicka, V., Groß, W.: Apolipoprotein E to B ratio: a marker for type III hyperlipoproteinaemia. Eur. J. Clin. Chem. Clin. Biochem. 31, 743-747, 1993
39. Russ, A.P., März, W., Ruzicka, V., Stein, U., Groß, W.: Rapid detection of the hypertension-associated Met235→Thr allele of the human angiotensinogen gene. Hum. Mol. Genet. 2, 609-610, 1993
40. Winkelmann, B.R., Ihnken, K., Beyersdorf, F., Eckel, L., Skupin, M., März, W., Herrmann, G., Spies, H., Schräder, R., Sievert, H.: Left main coronary artery stenosis after aortic valve replacement: genetic disposition for accelerated arteriosclerosis after injury of the intact human coronary artery? Coronary Artery Disease 4, 659-667, 1993
41. Ruzicka, V., März, W., Russ, A., Fisher, E., Mondorf, W., Groß, W.: Characterization of the gene for apolipoprotein E5-Frankfurt (Gln81→Lys, Cys112→Arg) by polymerase chain reaction, restriction isotyping, and temperature gradient gel electrophoresis. Electrophoresis 14, 1032-1037, 1993
42. März, W., Beckmann, A., Scharnagl, H., Siekmeier, R., Mondorf, U., Held, I., Schneider, W., Preissner K.T., Curtiss, L.K., Groß, W., Hüttinger, M.: Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/α2-macroglobulin receptor. FEBS Lett. 325, 271-275, 1993
43. März, W., Baumstark, M.W., Scharnagl, H., Ruzicka, V., Buxbaum, S., Herwig, J., Pohl, T., Russ, A., Schaaf, L., Berg, A., Böhles, H.-J., Usadel, K.H., Groß, W.: Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patient with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor. J. Clin. Invest. 92, 2922-2933, 1993
44. Föhrenbach, R., Lohrer, H., März, W., Siekmeier, R., Evangeliou, A., Böhles, H.-J.: L-Carnitin bei Hochleistungssportlern unterschiedlicher Disziplinen. Österreich. J. Sportmed. 3, 67-75, 1993
45. Föhrenbach, R., März, W., Lohrer, H., Siekmeier, R., Evangeliou, A., Böhles, H.-J.: Der Einfluß von L-Carnitin auf den Lipidstoffwechsel von Hochleistungssportlern. Deutsche Zeitschrift für Sportmedizin 44, 349-356, 1993
46. Kuhl, H., März, W., Jung-Hoffmann, C., Weber, J., Siekmeier, R., Groß, W.: Effect on lipid metabolism of a biphasic desogestrel-containing oral contraceptive: divergent changes in apolipoprotein B and E and transitory decrease in Lp(a) levels. Contraception 47, 69-83, 1993
47. März, W., Grützmacher, P., Paul, D., Siekmeier, R., Schoeppe, W., Groß, W.: Effects of lovastatin (20-80 mg daily) on lipoprotein fractions in patients with severe primary hypercholesterolaemia. Int. J. Clin. Pharmacol. Ther. Toxicol. 32, 92-97, 1994
48. Winkelmann, B.R., Siekmeier, R., Kullmer, T., Proft, M., Schneider, W., März, W.: Genetischer Polymorphismus des Apolipoprotein E - ein Vergleich zwischen Koronarkranken und Gesunden. Herz/Kreisl. 26, 194-199, 1994Chen, M., März, W., Usadel, K.H., Scheurmann, E.H., Böhm, B.O.: Typing of the HLA-DRB3 gene by temperature gradient gel electrophoresis. Prediction of the resolution of four allelic fragments by computational simulation of DNA melting. J. Immunol. Meth. 168, 257-265, 1994
50. Groß, E., März, W., Siekmeier, R., Scharrer, I., Groß, W.: Isolation of lipoprotein (a) using the regenerate of a dextran sulfate cellulose LDL apheresis system. Protein Expres. Purif. 5, 112-117, 1994
51. Siekmeier, R., März, W., Kronenberger, H., Seiffert, U.B., Groß, W.: Effects of cigarette smoking on plasma lipids, apolipoproteins, and lipoprotein(a) in healthy subjects. Clin. Chem. 40, 1350-1351, 1994
52. März, W., Schmitz, H., Bach, G., Kirchgässler, K.U., Pfützner, A.: Mikronisiertes Fenofibrat. Wirksamkeit und Verträglichkeit in der Therapie von Dyslipidämien. Münch. Med. Wschr. 136, 690-694, 1994
53. Haak, T., März, W., Jungmann, E., Hausser, S., Siekmeier, R., Groß, W., Usadel, K.-H.: Elevated endothelin levels in patients with hyperlipoproteinemia. Clin. Invest. 72, 580-584, 1994
54. Durovic, S., März, W., Frank, S., Scharnagl, H., Baumstark, M.W., Zechner, R., Kostner, G.M.: Decreased binding of apolipoprotein (a) to familial defective apolipoprotein B-100 (Arg3500→Gln). A study of the assembly of recombinant apolipoprotein (a) with mutant low density lipoproteins. J. Biol. Chem. 269, 30320-30325, 1994
55. Ohm, T.G., Kirça, M., Bohl, J., Scharnagl, H., Groß, W., März, W.: Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 66, 583-587, 1995
56. Scharnagl, H., März, W., Schliack, M., Löser, R., Groß, W.: A novel assay for cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase activity using reversed-phase ion-pair chromatography: demonstration that Lifibrol (K12.148) modulates the enzyme activity. J. Lipid. Res. 36, 622-627, 1995
57. März, W., Seydewitz, H., Winkelmann, B.R., Chen, M., Nauck, M., Witt, I.: Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 345, 526-527, 1995 (Letter)
58. Nauck, M., Winkler, K., Wittmann, C., Mayer, H., Luley, C., März, W., Wieland, H.: Direct determination of lipoprotein(a) cholesterol by ultracentrifugation and agarose gel electrophoresis with enzymatic staining for cholesterol. Clin. Chem. 41, 731-738, 1995
59. Nauck, M., Winkler, K., Siekmeier, R., Marangos, N., Richter, B., März, W., Wieland, H.: Pseudo-pseudohypertriglyceridemia: a case of increased free glycerol without evidence for glycerol kinase deficiency. Clin. Chem. 41, 619-620, 1995
60. Winkler, K., Nauck, M., Siekmeier, R., März, W., Wieland, H.: Determination of triglycerides in lipoproteins separated by agarose gel electrophoresis. J. Lipid Res. 36, 1839-1847, 1995
61. Kuhl, H., Jung-Hoffmann, C., Fitzner, M., März, W., Groß, W.: Short- and long-term effects on lipid metabolism of oral contraceptives containing 30 micrograms ethinylestradiol and 150 micrograms desogestrel or 3-keto-desogestrel. Horm. Res. 44, 121-125, 1995
62. Nauck, M., Winkler, K., März, W., Wieland, H.: Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein (a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clin. Chem. 41, 1761-1767, 1995
63. Kullmer, T., Kneissl, G., Katova, T., Kronenberger, H., Urhausen, A., Kindermann, W., März, W., Meier-Sydow, J.: Experimental acute hypoxia in healthy subjects: evaluation of systolic and diastolic function of the left ventricle at rest and during exercise using echocardiography. Eur. J. Appl. Physiol. 70, 169-174, 1995
64. Zhang, Q., Cavanna, J., Winkelmann, B.R., Shine, B., Groß, W., März, W., Galton, D.J.: Common genetic variants of lipoprotein lipase that relate to lipid transport in patients with premature coronary artery disease. Clin. Genet. 48, 293-298, 1995
65. Nauck, M., März, W., Haas, B., Wieland, H.: Homogeneous assay for direct determination of high-density lipoprotein cholesterol evaluated. Clin. Chem. 42, 424-429, 1996
66. Feussner, G., Scharnagl, H., Scherbaum, C., Acar, J., Dobmeyer, J., Lohrmann, J., Wieland, H., März, W.: Apolipoprotein E5 (Glu212→Lys): increased binding to cell surface proteoglycans, but decreased uptake and lyosomal degradation in cultured fibroblasts. J. Lipid Res. 37, 1632-1645, 1996
67. Siekmeier, R., Wülfroth, P., Wieland, H., Groß, W., März, W.: Low-density lipoprotein susceptibility to in vitro oxidation in healthy smokers and nonsmokers. Clin. Chem. 42, 524-530, 1996
68. Siekmeier, R., März, W., Scharnagl, H., Nauck, M., Mayer, H., Wieland, H., Groß, W., Seiffert, U.B.: Bestimmung von Lipoprotein(a): Vergleich eines neuen latexverstärkten immunoturbidimetrischen Assay mit einem immunoradiometrischen Assay. J. Lab. Med. 20, 294-298, 1996
69. Winkelmann, B.R., Nauck, M., Klein, B., Russ, A.P., Böhm, B.O., Siekmeier, R., Ihnken, K., Verho, M., Groß, W., März, W.: Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with increased plasma angiotensin-converting enzyme activity but not with increased risk of myocardial infarction and coronary artery disease. Ann. Intern. Med. 125, 19-25, 1996
70. Nauck, M., März, W., Wieland, H.: Adding albumin normalizes electrophoretic mobility of lipoproteins in sera with high concentrations of free fatty acids. Clin. Chem. 42, 1283-1285, 1996
71. Nauck, M., Krämer-Guth, A., Bartens, W., März, W., Wieland, H., Wanner, C.: Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients?
72. Oemar, B.S., Werner, A., Garnier, J.-M., Do, D.-D., Godoy, N., Nauck, M., März, W., Rupp, J., Pech, M., Lüscher, T.F.: Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 95, 831-839, 1997
73. Schaefer, J.R., Scharnagl, H., Baumstark, M.W., Steinmetz, A., Schweer, H., Zech, L.A., Seyberth, H., Winkler, K., März, W.: Homozygous familial defective apolipoprotein B-100: enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler. Thromb.Vasc. Biol. 17, 348-353, 1997
74. Lindh, M., Blomberg, M., Jensen, M., Basun, H., Lannfeldt, L., Engvall, B., Scharnagl, H., März, W., Wahlund, L.-O., Cowburn, R.F.: Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer´s disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci. Lett. 229, 85-88, 1997
75. Krämer-Guth, A., Quaschning, T., Pavenstädt, H., Galle, J., Nauck, M., Baumstark, M.W., Schollmeyer, P., März, W., Wanner, C.: Uptake and metabolism of lipoproteins from patients with diabetes mellitus type II by glomerular epithelial cells. Nephrol. Dial. Transplant. 12, 1336-1343, 1997
76. Krämer-Guth, A., Quaschning, T., Galle, J., Baumstark, M.W., Königer, M., Nauck, M., Schollmeyer, P., März, W., Wanner, C.: Structural and compositional modifications of diabetic low-density lipoproteins influence their receptor-mediated uptake by hepatocytes. Eur. J. Clin. Invest. 27, 460-468, 1997
77. Zhang, Q., Cavallero, E., Hoffmann, M.M., Cavanna, J., Kay, A., Charles, A., Braschi, S., März, W., Perlemuter, L., Jacotot, B., Galton, D.J.: Mutations at the lipoprotein lipase gene locus in subjects with diabetes mellitus, obesity and lipaemia. Clin. Sci. 93, 335-341, 1997
78. Winkelmann, B.R., Nauck, M., März, W.: Reliability of angiotensin-converting enzyme gene polymorphism in testing. Ann. Intern. Med. 126, 828, 1997 (Letter)
79. Nauck, M., März, W., Jarausch, J., Cobbaert, C., Sägers, A., Bernard, D., Delanghe, J., Honauer, G., Lehmann, P., Östrich, E., von Eckardstein, A., Walch, S., Wieland, H., Assmann, G.: Multicenter evaluation of a homogeneous assay for HDL-cholesterol without sample pretreatment. Clin. Chem. 43, 1622-1629, 1997
80. Wolf, R., Orszagh, M., März, W., Rösler, N., Berger, M., Bauer, J.: Case study. Revision of an Alzheimer´s diagnosis in a patient with an almost normal CT scan: why strategic vascular lesions may be overlooked. Alzheimer´s Research 3, 73-76, 1997Bommer, C., Werle, E., Walter-Sack, I., Keller, C., Gehlen, F., Wanner, C., Nauck, M., März, W., Wieland, H., Bommer, J.: D-tyroxine reduces lipoprotein(a) serum concentration in dialysis patients. J. Am. Soc. Nephrol. 9, 90-96, 1998 März, W., Hoffmann, M.M., Scharnagl, H., Fisher, E., Chen, M., Nauck, M.S., Feussner, G., Wieland, H.: Apolipoprotein E2 (Arg136→Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia. J. Lipid. Res. 39, 658-669, 1998
83. Feussner, G., Feussner, V., Hoffmann, M.M., Lohrmann, J., Wieland, H., März, W.: Molecular basis of type III hyperlipoproteinemia. Hum. Mutat. 11, 417-423, 1998
84. Zotz, R.B., Winkelmann, B.R., Nauck, M., Giers, G., Maruhn-Debowski, B., März, W., Scharf, R.E.: Polymorphism of platelet membrane glycoprotein IIIa: human platelet antigen 1b (HPA-1b/PIA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb. Haemost. 79, 731-735, 1998
85. Nauck, M.S., Nissen, H., Hoffmann, M.M., Herwig, J., Pullinger, C.R., Averna, M., Geisel, J., Wieland, H., März, W.: Detection of mutations in the apolipoprotein CII gene by denaturing gradient gel electrophoresis. Identification of the splice site variant apolipoprotein CII-Hamburg in a patient with severe hypertriglyceridemia. Clin. Chem. 44, 1388-1396, 1998
86. Nauck, M., März, W., Wieland, H.: New immunoseparation-based homogeneous assay for HDL-cholersterol compared with three homogeneous and two heterogeneous methods for HDL-cholesterol. Clin. Chem. 44, 1443-1451, 1998
87. Cobbaert, C., Zwang, L., Ceriotti, F., Modenese, A., Cremer, P., Herrmann, W., Hoß, G., Jarausch, J., Türk, R., März, W., Nauck, M.: Reference standardization and triglyceride interference of a new homogeneous HDL-cholesterol assay compared with al former chemical precipitation assay. Clin. Chem. 44, 779-789, 1998
88. Braun, J., März, W., Winkelmann, B.R., Donner, H., Usadel, K.H., Badenhoop, K.: Tumour necrosis factor ß alleles and hyperinsulinaemia in coronary artery disease. Eur. J. Clin. Invest. 28, 538-542, 1998
89. Hennermann, J.B., Herwig, J., März, W., Asskali, F., Böhles, H.J.: Lipid and lipoprotein profiles in children with familial hypercholesterolaemia: effects of therapy. Eur. J. Pediatr. 157, 912-918, 1998
90. Szucs, T.D., Guggenberger, G., Berger, K., März, W., Schäfer, J.R.: Pharmakoökonomische Bewertung von Pravastatin in der Sekundärprävention der koronaren Herzkrankheit bei Patienten mit durchschnittlichen Cholesterinwerten. Herz 23, 319-329, 1998
91. Müller, W., Meske, V., Berlin, K., Scharnagl, H., März, W., Ohm, T.G.: Apolipoprotein E isoform increase intracellular Ca2+ differentially through a ω-Agatoxin IVa-sensitive Ca2+-channel. Brain Pathol. 8, 641-653, 1998
92. Bissé, E., Zorn, N., Eigel, A., Lizama, M., Huaman-Guillen, P., März, W., Van Dorsselaer, A., Wieland, H.: Hemoglobin Rambam (ß69[E13]Gly→Asp), a pitfall in the assessment of diabetic control: characterization by electrospray mass spectrometry and HPLC. Clin. Chem. 44, 2172-2177, 1998
93. Szucs, T.D., März, W.: Cost effectiveness of coronary prevention. Eur. Heart J. 20, 317, 1999 (Letter)
94. Winkler, K., Scharnagl, H., Tisljar, U., Hoschützky, H., Friedrich, I., Hoffmann, M.M., Hüttinger, M., Wieland, H., März, W.: Competition of Aß amyloid peptide and apolipoprotein E for receptor-mediated endocytosis. J. Lipid Res. 40, 447-455, 1999
95. Winkelmann, B.R., Russ, A.P., Nauck, M., Klein, B., Böhm, B.O., Maier, V., Zotz, R., Matheis, G., Wolf, A., Wieland, H., Groß, W., Galton, D.J., März, W.: Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am. Heart J. 137, 698-705, 1999
96. März, W., Wollschläger, H., Klein, G., Neiß, A., Wehling, M.: Safety of low density lipoprotein cholesterol reduction with Atorvastatin versus Simvastatin in a coronary heart disease population (the TARGET TANGIBLE Trial). Am. J. Cardiol. 84, 7-13, 1999
97. Winkler, K., Schäfer, J.R., Klima, B., Nuber, C., Sattler, A., Friedrich, I., Köster, W., Steinmetz, A., Wieland, H., März, W.: Lifibrol enhances low density lipoprotein apolipoprotein B-100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia. Atherosclerosis 144, 167-175, 1999
98. Nauck, M.S., Gierens, H., Nauck, M.A., März, W., Wieland, H.: Rapid genotyping of human platelet antigen 1 (HPA-1) with fluorophore-labelled hybridization probes on the LightCyclerTM. Br. J. Haematol. 105, 803-810, 1999
99. Wanner, C., Krane, V., Ruf, G., März, W., Ritz, E., for Die Deutsche Diabestes Dialyse Studie Investigators: Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis: The 4D study. Kidney Int. 56 (Suppl. 71), S222-S226, 1999
100. Nauck, M., Glatt, L., März, W., Feussner, G., Wieland, H.: Simple precipitation-based method for the screening of type III hyperlipoproteinemia. Clin. Chem. 45, 909-911, 1999
101. Larson, I., Hoffmann, M.M., Ordovas, J.M., Schaefer, E.J., März, W., Kreuzer, J.: The lipoprotein lipase HindIII polymorphism: association with total cholesterol and LDL-cholesterol, but not with HDL and triglycerides in 342 females. Clin. Chem. 45, 963-968, 1999
102. Fisher, E., Scharnagl, H., Hoffmann, M.M., Kusterer, K., Wittmann, D., Wieland, H., Groß, W., März, W.: Mutations in the apolipoprotein (apo) B-100 receptor-binding region: detection of apo B-100 (arg3500→trp) associated with two new haplotypes and evidence that apo B-100 (glu3405→ gln) diminishes receptor-mediated uptake of LDL. Clin Chem. 45, 1026-1038, 1999
103. Nauck, M.S., Wieland, H., März W.: Rapid homogeneous genotyping of the 4G/5G polymorphism in the promoter region of the PAI-1 gene by fluorescence resonance energy transfer and probe melting curves. Clin. Chem. 45, 1141-1147, 1999
104. Kusterer, K., Pohl, T., Fortmeyer, H.-P., März, W., Scharnagl, H., Oldenburg, A., Angermüller, S., Fleming, I., Usadel, K.H., Busse, R.: Chronic selective hypertriglyceridemia impairs endothelium-dependent vasodilation in rats. Cardiovasc. Res. 42, 783-793, 1999
105. Nauck, M., Neumann, I., März, W., Wieland, H.: A new liquid homogeneous assay for the determination of HDL-cholesterol. A comparison to precipitation with phosphotungstic acid/MgCl2 and a lyophilized homogeneous assay. Clin. Chem. Lab. Med. 37, 537-543, 1999
106. Ohm, T.G., Scharnagl, H., März, W., Bohl, J.: Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol. 98, 273-280, 1999
107. Scharnagl, H., Tisljar, U., Winkler, K., Hüttinger, M., Nauck, M.A., Groß, W., Wieland, H., Ohm, T.G., März, W.: The ßA4 amyloid peptide complexes to and enhances the uptake of ß-very low density lipoproteins by the low density lipoprotein receptor-related protein and heparan sulfate proteoglycans pathway. Lab. Invest. 79, 1271-1286, 1999
108. Koenig, W., Rothenbacher, D., Hoffmeister, A., Miller, M., Bode, G., Adler, G., Hombach, V., März, W., Pepys, M.B., Brenner, H.: Infection with Helicobacter pylori is not a major independent risk factor for stable coronary heart disease. Lack of a role of Cytotoxin-associated protein a-positive strains and absence of a systemic inflammatoriy response. Circulation 100, 2326-2331, 1999
109. Wetzka, B., Winkler, K., Kinner, M., Friedrich, I., März, W., Zahradnik, H.P.: Altered lipid metabolism in preeclampsia and HELLP syndrome: Links to enhanced platelet reactivity and fetal growth. Semin. Thromb. Haemost. 25, 455-462, 1999
110. Nauck, M.S., Nauck, M.A., Nauck, M., März, W., Wieland, H.: Six methods for the determination of C-peptide evaluated, Clin. Chem. Lab. Med. 37: 745-752, 1999
111. Nauck, M., Graziani, M.S., Jarausch, J., Bruton, D., Cobbaert, C., Cole, T.G., Colella, F., Lefevre, F., Gillery, P., Haas, B., Law, T., König, M., Macke, M., März, W., Meier, C., Riesen, W., van Vliet, M., Wieland, H., Rifai, N.: A new liquid homogeneous assay for HDL cholesterol determination evaluated in seven laboratories in Europe and the United States. Clin. Chem. Lab. Med. 37, 1067-1076, 1999
112. Schuler-Lüttmann, S., Zhu, Y., Hoffmann, M.M., März, W., Feussner, G., Wieland, H., Assmann, G., von Eckardstein, A.: Cholesterol efflux from normal and Tangier disease fibroblasts into normal, high density lipoprotein-deficient, and apolipoprotein E-deficient plasmas. Metabolism 49, 770-777, 2000
113. Nauck, M., Hoffmann, M.M., Wieland, H., März, W.: Evaluation of the apo E genotyping kit on the Light-Cycler. Clin. Chem. 46, 722-724, 2000
114. Winkler, K., Schaefer, J.R., Klima, B., Nuber, C., Friedrich, I., Köster, W., Gierens, H., Scharnagl, H., Soufi, M., Wieland, H., März, W.: HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lifibrol in patients with hypercholesterolemia and mixed hyperlipidemia. Atherosclerosis 150, 113-120, 2000
115. Nauck, M.S., Scharnagl, H., Nissen, H., Schürmann, C., Matern, D., Nauck, M.A., Wieland, H., März, W.: FH-Freiburg: a novel missense mutation (C317Y) in growth factor repeat A of the low density lipoprotein receptor gene in a German patient with homozygous familial hypercholesterolemia. Atherosclerosis 151, 525-534, 2000
116. Nauck, M., Roser, M., März, W., Wieland, H.: Additional comments on pre-analytical aspects of lipoprotein measurement (Letter). Clin. Lab. 46, 301-302, 2000
117. Schaefer, J.R., Winkler, K., Schweer, H., Hoffmann, M.M., Soufi, M., Scharnagl, H., Maisch, B., Wieland, H., Steinmetz, A., März, W.: Increased production of HDL apoA-I in homozygous familial defective apoB-100. Arterioscler. Thromb. Vasc. Biol. 20, 2000, 1796-1799
118. Gierens, H., Nauck, M., Roth, M., Schinker, R., Schürmann, C., Scharnagl, H., Neuhaus, G., Wieland, H., März W.: Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements. Arterioscler. Thromb. Vasc. Biol. 20, 1777-1783, 2000
119. Nauck, M., März, W., Wieland, H.: Is lipoprotein(a) cholesterol a significant indicator of cardiovascular risk ? (Letter) Clin. Chem. 46, 436-437, 2000
120. Siekmeier, R., Groß, W., März, W.: Determination of Pravastatin by high performance liquid chromatography. Int. J. Clin. Pharmacol. Ther. 38, 419-425, 2000
121. Szucs, T.D., Berger, K., März, W., Schäfer, J.R.: Kosteneffektivität von Pravastatin in der koronaren Sekundärprävention bei Patienten mit Myokardinfarkt und instabiler Angina pectoris in Deutschland. Eine Analyse auf der Grundlage der LIPID-Studie. Herz 25, 487-494, 2000
122. Nauck, M., Wieland, H., März, W.: Evaluation of the Roche Diagnostics LightCycler-Apo B 3500 mutation detection kit. Clin. Chem. Lab. Med. 38, 667-671, 2000
123. Nauck, M.S., März, W., Wieland, H.: Evaluation of the Roche Diagnostics LightCycler-Factor V Leiden Mutation Detection Kit and the LightCycler-Prothrombin Mutation Detection Kit. Clin. Biochem. 33, 213-216, 2000
124. Gibb, G.M., Pearce, J., Betts, J.C., Lovestone, S., Hoffmann, M.M., März, W., Blackstock, W.P., Anderton, B.H.: Differential effects of apolipoprotein E isoforms on phosphorylation at specific sites on tau by glycogen synthase kinase-3β identified by nano-electrospray mass spectrometry. FEBS Lett. 485, 99-103, 2000 Scharnagl, H., Schliack, M., Löser, R., Nauck, M., Gierens, H., Jeck, N., Wieland, H., Groß, W., März, W.: The effects of Lifibrol (K12.148) on the cholesterol metabolism of cultured cells: evidence for sterol independent stimulation of the LDL receptor pathway. Atherosclerosis 153, 69-80, 2000
126. März, W., Siekmeier, R., Müller, H.-M., Wieland, H., Groß, W., Olbrich, H.-G.: Effects of Lovastatin and Pravastatin on the survival of hamsters with inherited cardiomyopathy. J. Cardiovasc. Pharmacol. Ther. 5, 275-279, 2000
127. Winkler, K., Wetzka, B., Hoffmann, M.M., Friedrich, I., Kinner, M., Baumstark, M.W., Wieland, H., März, W., Zahradnik, H.P.: Low density lipoprotein (LDL) subfractions during pregnancy: accumulation of buoyant LDL with advancing gestation. J. Clin. Endocrinol. Metab. 85, 4543-4550, 2000
128. Huber, G., März, W., Martin, J.R., Malherbe, P., Richards, J.G., Sueoka, N., Ohm, T., Hoffmann, M.M.: Characterization of transgenic mice expressing apolipoprotein E4(C112R) and apolipoprotein E4 (L28P; C112R). Neuroscience 101, 211-218, 2000
129. Hoffmann, M.M., Jacob, S., Luft, D., Schmülling, R.-M., Rett, K., März, W., Häring, H.-U., Matthaei, S.: Type I hyperlipoproteinemia due to a novel loss of function mutation of lipoprotein lipase, Cys239→Trp, associated with recurrent severe pancreatitis. J. Clin. Endocrinol. Metab. 85, 4795-4798, 2000
130. Nauck, M., Stein, U., Karger, S., März, W., Wieland, H.: Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridzation probes. Clin. Chem. 46, 1995-1997, 2000
131. Fisher, E., März, W., Groß, W.: High prevalence of FDB3500 mutation in the Swiss population. Atherosclerosis 153, 519-521, 2000 (Letter)
132. Hoffmann, M.M., Scharnagl, H., Panagiotou, E., Banghard, W.T., Wieland, H., März W.: Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J. Am. Soc. Nephrol. 12, 524-530, 2001
133. Masana, L.I., Febrer, G., Cavanna, J., Baroni, M.G., März, W., Hoffmann, M.M., Shine, B., Galton, D.J.: Common genetic variants that relate to disorders of lipid transport in Spanish subjects with premature coronary artery disease. Clin. Sci. 100, 183-190, 2001
134. Hoffmann, M.M., Scharnagl, H., Köster, W., Winkler, K., Wieland, H., März, W.: Apolipoprotein E1-Baden (Arg180→Cys): a new apolipoprotein E variant associated with hypertriglyceridemia. Clin. Chim. Acta, 303, 41-48, 2001
135. Hoffmeister, A., Rothenbacher, D., Bode, G., Persson, K., März, W., Nauck, M.A., Brenner, H., Hombach, V., Koenig, W.: Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile. Ateroscler. Thromb. Vasc. Biol. 21, 427-432, 2001
136. Ritzel, R., Schulte, M., Porksen, N., Nauck, M.S., Holst, J.J., Juhl, C., März W., Schmitz, O., Schmiegel, W.H., Nauck, M.A.: Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes 50, 776-784, 2001
137. März, W., Scharnagl, H., Abletshauser, C., Hoffmann, M.M., Berg, A., Keul, J., Wieland, H., Baumstark, M.W.: Fluvastatin lowers atherogenic, dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation, 103, 1942-1948, 2001
138. Kojro, E., Gimpl, G., Lammich, S., März, W., Fahrenholz F.: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. USA 98, 5815-5820, 2001
139. Winkelmann, B.R., März, W., Böhm, B.O., Zotz, R., Hager, J., Hellstern, P., Senges, J. on behalf of the LURIC study group: Rationale and design of the LURIC study – a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2 (Suppl. 1), S1-S73, 2001
140. Scharnagl, H., Nauck, M., Wieland, H., März, W.: The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin. Chem. Lab. Med., 39, 426-431, 2001
141. Brenner, H., Rothenbacher, D., Bode, G., März, W., Hoffmeister, A., Koenig, W.: Coronary heart disease risk reduction in a predominantly beer-drinking population. Epidemiology 12, 390-395, 2001
142. Nauck, M., Gierens, H., März, W., Wieland, H.: Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxcity and congenital thymine uraciluria using fluorogenic hybridization probes. Clin. Biochem. 34, 103-105, 2001
143. Yates, R.A., Wong, J., Seiberling, M., Merz, M., März, W., Nauck, M.: The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br. J. Clin. Pharmacol. 51, 429-435, 2001
144. Nauck, M.S., Köster, W., Dörfer, K., Eckes, J., Scharnagl, H., Gierens, H., Nissen, H., Nauck, M.A., Wieland, H., März, W.: Identification of recurrent and novel mutations in the LDL receptor gene in German patients with familial hypercholesterolemia. Hum. Mutat. 18, 165-166, 2001
145. Scharnagl, H., Schinker, R., Gierens, H., Nauck, M., Wieland, H., März, W.: Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem. Pharmacol. 62, 1545-1555, 2001
146. Winkelmann, B.R., Böhm, B.O., Nauck, M.S., Kleist, P., März, W., Verho, N.K., Ranjith, N., Kneissl, G.: Cigarette smoking is independently associated with markers of endothelial dysfunction and hyperinsulinaemia in non-diabetic individuals with coronary artery disease. Curr. Med. Res. Opin. 17, 132-141, 2001
147. Park, J.-W., Siekmeier, R., Merz, M., Krell, B., Harder, S., März, W., Seidel, D., Schüler, S., Groß, W.: Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosprin A. Int. J. Clin. Pharmacol. Ther. 40, 439-450, 2002
148. Rothenbacher, D., Fischer, H.G., Hoffmeister, A., Hoffmann, M.M., März, W., Bode, G., Rosenthal, J., Koenig, W., Brenner, H.: Homocysteine and methylenetetrahydrofolate reductase genotype: association with risk of coronary heart disease and relation to inflammatory, hemostatic, and lipid parameters. Atherosclerosis 162, 193-200, 2002
149. Winkler, K., Friedrich, I., Baumstark, M.W., Wieland, H., März, W.: Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. Br. J. Diab. Vasc. Dis. 2, 143-148, 2002
150. Kay, A., März, W., Hoffmann, M.M., Zhang, Q., Masana, L., Cavanna, J., Baroni, M.G., Shine, B., Galton D.J.: Coronary artery disease and dyslipidemia within Europe: genetic variants in lipid transport gene loci in German subjects with premature coronary artery disease. Atherosclerosis Suppl. 3, 27-33, 2002
151. Ruof, J., Klein, G., März, W., Wollschläger, H., Neiss, A., Wehling M.: Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns. Prev. Med. 35, 48-53, 2002
152. Koenig, W., Khuseyinova, N., Hoffmann, M.M., März W., Fröhlich, M., Hoffmeister, A., Brenner, H., Rothenbacher, D.: CD14 C(-260)→T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease. J. Am. Coll. Cardiol. 40, 34-42, 2002
153. Abletshauser, C., Klüßendorf, D., Schmidt, A., Winkler, K., März, W., Buddecke, E. Malmsten, M., Siegel, G.: Biosensing of arteriosclerotic nanoplaque formation and interaction with an HMG-CoA reductase inhibitor. Acta Physiol. Scand. 176, 131-145, 2002
154. Wiemer, J., Winkler, K., Baumstark M., März, W., Scherberich, J.E.: Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. Nephrol. Dial. Transplant. 17, 2231-2238, 2002
155. Nauck, M., Winkelmann, B.R., Hoffmann, M.M., Böhm, B.O., Wieland, H., März, W.: C(-260)T polymorphism in the promoter of the CD14 gene is not associated with coronary artery disease and myocardial infarction in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Am. J. Cardiol. 90, 1249-1252, 2002
156. Nauck, M., Winkelmann, B.R., Hoffmann, M.M., Böhm, B.O., Wieland H., März, W.: The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction. J. Mol. Med. 80, 507-513, 2002
157. Winkler, K., Abletshauser, C., Hoffmann, M.M., Friedrich, I., Gläser, R., Baumstark, M.W., Wieland, H., März, W.: Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profiles determines specific mode of action. J. Clin. Endocrinol. Metab. 87, 5485-5490, 2002
158. Nauck, M.S., Scharnagl, H., Nissen, H., Schurmann, C., Matern, D., Nauck, M.A., Wieland, H., März, W.: Corrigendum to 'FH-Freiburg: a novel missense mutation (C317Y) in growth factor repeat A of the low density lipoprotein receptor gene in a German patient with homozygous familial hypercholesterolemia' (Atherosclerosis 151, 525-534, 2000 [Journal Article]). Atherosclerosis 167, 173, 2003
159. Spaniol, M., Kaufmann, P., Beier, K., Wüthrich, J., Török, M., Scharnagl, H., März, W., Krähenbühl, S.: Mechanisms of liver steatosis in rats with systemic carnitine deficiency due to treatment with trimethylhadraziniumpropionate. J. Lipid Res. 44, 144-153, 2003
160. The ENCORE Investigators: Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease. The ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function) Circulation 107, 422-428, 2003
161. Winkler, K., Wetzka, B., Hoffmann, M.M., Friedrich, I., Kinner, M., Baumstark, M.W., Zahradnik, H.-P., Wieland, H., März, W.: Triglyceride-rich lipoproteins are associated with hypertension in preeclampsia. J. Clin. Endocrinol. Metab. 88, 1162-1166, 2003
162. Ljungberg, M.C., Asuni, A., Pearce, J., Dayanandan, R., März, W., Hoffmann, M.M., Bertrand, P., Siest, G., Rupniak, H.T.R., Anderton, B.H., Huettinger, M., Lovestone S.: Apolipoprotein E (apoE) uptake and distribution in mammilian cell lines is dependent upon source of apoE and can be monitored in living cells. Neurosci. Lett. 341, 69-73, 2003
163. Taubert, G., Winkelmann, B.R., Schleiffer, T., März, W., Winkler, R., Gök, R., Klein, B., Schneider, S., Böhm, B.O.: Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am. Heart J. 145, 285-291, 2003
164. Marx, N., Imhof, A., Fröhlich, J., Siam, L., Ittner, J., Wierse, G., Schmidt, A., Maerz, W., Hombach, V., Koenig, W.: Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 107, 1954-1957, 2003
165. Winkler, K., Konrad, T., Füllert, S., Friedrich, I., Destani, R., Baumstark, M.W., Krebs, K., Wieland, H., März, W.: Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 26, 2588-2594, 2003 7.501 {
166. Manzoni, C., Duranti, M., Eberini, I., Scharnagl, H., März, W., Castiglioni, S., Lovati, M.R.: Subcellular localization of soybean 7S globulin in HepG2 cells and LDL receptor up-regulation by its alpha' constituent subunit. J. Nutr. 133, 2149-2155, 2003 3.321 {Winkelmann, B.R., Hoffmann, M.M., Nauck, M., Kumar, A.M., Nandabalan, K., Judson, R.S., Böhm, B.O., Tall, A.R., Ruaño, G., März, W.: Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy. Pharmacogenomics J. 3, 284-296, 2003
168. März, W., Winkler, K., Nauck, M., Böhm, B.O., Winkelmann, B.R.: Effects of statins on C-reactive protein and on interleukin 6 (The Ludwigshafen Risk and Cardiovascular Health Study). Am. J. Cardiol. 92, 305-308, 2003
169. Bugert, P., Hoffmann, M.M., Winkelmann, B.R., Vosberg, M., Jahn, J., Entelmann, M., Katus, H.A., März, W., Mansmann, U., Böhm, B.O., Goerg, S., Klüter, H.: The variable number of tandem repeat polymorphism in the P-selectin glycoprotein ligand-1 gene is not associated with coronary heart disease. J. Mol. Med. 81, 495-501, 2003 4.101 {
170. Imhof, A., Rothenbacher, D., Khuseyinova, N., Hoffmeister, A., März, W., Nauck, M., Scharnagl, H., Koenig, W., Brenner, H.: Plasma lipoprotein Lp(a), markers of hemostasis and inflammation, and risk and severity of coronary heart disease. Eur. J. Cardiovasc. Prev. Rehabil. 10, 362-370, 2003
171. Miserez, A.R., Scharnagl, H., Muller, P.Y., Mirsaidi, R., Stähelin, H.B., Monsch, A., März, W., Hoffmann, M.M.: Apolipoprotein E3Basel: new insights into a highly conserved protein region. Eur. J. Clin. Invest. 33, 677-685, 2003
172. Lang, T.H., Toller, W.G., Gütl, M., Mahla, E., Metzler, H., Rehak, P.H., März, W., Halwachs-Baumann, G.: Different effects of abciximab and cytochalasin D on clot strength in thrombelastography. J. Thromb. Haemost. 2, 147-153, 2004
173. Scharnagl, H., Kist, H., Busse-Grawitz, A., Koenig, W., Wieland, H., März, W.: Effect of Helicobacter pylori eradication on high-density lipoprotein cholesterol. Am. J. Cardiol. 93, 219-220, 2004
174. Scharnagl, H., Petersen, G., Nauck, M., Teichmann, A.T., Wieland, H., März, W.: Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 µg or 30 µg) and levonorgestrel (100 µg or 150 µg) on lipoprotein metabolism. Contraception 69, 105-113, 2004
175. Wetzka, B., Hoffmann, M.M., Friedrich, I., Baumstark, M.W., Zahradnik, H.-P.,März, W., Winkler, K.: Transient remnant removal disease in acute fatty liver of pregnancy. Hypertens. Pregnancy 23, 143-153, 2004
176. Soufi, M., Sattler, A.M., März, W., Starke, A., Herzum, M., Maisch, B., Schaefer, J.R.: A new but frequent mutation of ApoB-100 – apoB His3543Tyr. Atherosclerosis 174, 11-16, 2004
177. Winkler, K., Weltzien, P., Friedrich, I., Schmitz, H., Nickell, H.H., Hauck, P., Hoffmann, M.M., Baumstark, M.W., Wieland, H., März, W.: Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. Exp. Clin. Endocrinol. Diabetes 112, 241-247, 2004
178. Scharnagl, H., Winkler, K., Mantz, S., Baumstark, M.W., Wieland, H., März, W.: Inhibition of HMG-CoA reductase with Cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 112, 269-277, 2004
179. Winkler, K., Abletshauser, C., Friedrich, I., Hoffmann, M.M., Baumstark, M.W., Wieland, H., März, W.: Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 1153-1159, 2004
180. März, W., Nauck, M., Hoffmann, M.M., Nagel, D., Böhm, B.O., Koenig, W., Rothenbacher, D., Winkelmann, B.R.: G(-30)A polymorphism in the pancreatic promoter of the glucokinase gene associated with angiographic coronary artery disease and type 2 diabetes mellitus. Circulation 109, 2844-2849, 2004
181. Patsouris, D., Mandard, S., Voshol, P.J., Escher, P., Tan, N.S., Havekes, L.M., Koenig, W., März, W., Tafuri, S., Wahli, W., Müller, M., Kersten, S.: PPARalpha governs glycerol metabolism. J. Clin. Invest. 114, 94-103, 2004
182. Mangge, H., Schauenstein, K., Stroedter, L., Griesl, A., März, W., Borkenstein, M.: Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp. Clin. Endocrinol. Diabetes 112, 378-382, 2004
183. März, W., Scharnagl, H., Winkler, K., Tiran, A., Nauck, M., Böhm, B.O., Winkelmann, B.R.: Low density lipoprotein triglycerides associated with low grade systemic inflammation, adhesion molecules and angiographic coronary disease. (The Ludwigshafen Risk and Cardiovascular Health Study). Circulation 110, 3068-3074, 2004
184. März, W., Scharnagl, H., Böhm, B.O., Winkelmann, B.R.: The apolipoprotein E polymorphism is associated with circulating C-reactive protein (The Ludwigshafen Risk and Cardiovascular Health Study). Eur. Heart J. 25, 2109-2119, 2004
185. Simeoni, E., Winkelmann, B.R., Hoffmann, M.M., Fleury, S., Ruiz, J., Kappenberger, L., März, W., Vassalli, G.: Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur. Heart J. 25, 1438-1446, 2004
186. Simeoni, E., Hoffmann, M.M., Winkelmann, B.R., Ruiz, J., Fleury, S., Böhm, B.O., März, W., Vassalli, G.: Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia 47, 1574-1580, 2004
187. Vetter, S., Ruf, G., Regourd, E., März, W.: The use of atorvastatin treatment in usual care environments: pooled analysis of six prospective, observational studies in 90,535 patients. Int. J. Clin. Pharmacol. Ther. 42, 423-433, 2004
188. Wanner, C., Krane, V., März, W., Olschewski, M., Asmus, H.G., Krämer, W., Kühn, K.W., Kütemeyer, H., Mann, J.F., Ruf, G., Ritz, E.: Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics. Kidney Blood Press Res. 27, 259-266, 2004
189. März, W., Böhm, B.O., Winkelmann, B.R., Hoffmann, M.M.: The PlA1/A2 polymorphism of platelet glycoprotein IIIa is not associated with the risk of type 2 diabetes. The Ludwigshafen Risk and Cardiovascular Health Study. Diabetologia 47,1969-1973, 2004
190. Renner, W., Grammer, T., Hoffmann, M.M., Nauck, M.S., Winkelmann, B.R., Böhm B.O., März, W.: Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J. Hypertens. 22, 2398-2399, 2004 (Letter)
191. Weger, M., Steinbrugger, I., Haas, A., März, W., El-Shabrawi, Y., Weger, W., Schmut, O., Renner, W.: Role of the interleukin-6 – 174 G>C gene polymorphism in retinal artery occlusion. Stroke 36, 249-252, 2005
192. Renner, W., Nauck, M., Winkelmann, B.R., Hoffmann, M.M., Scharnagl, H., Böhm, B.O., März, W.: Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. J. Mol. Med. 83, 235-239, 2005
193. Winkler, K., Winkelmann, B.R., Scharnagl, H., Hoffmann, M.M., Grawitz, A.B., Nauck, M., Böhm, B.O., März, W.: Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors. The Ludwigshafen Risk and Cardiovascular Health Study. Circulation 111, 980-987, 2005
194. Winkler, K., Hoffmann, M.M., Busse-Grawitz, A., Nauck, M., Winkelmann, B.R., Scharnagl, H., März, W., Böhm, B.O.: Response to Ewa Ninio: Letter regarding article by Winkler et al., Circulation 2005; 111: 980-987. Circulation 112, e108-e109, 2005
195. Wittchen, H.-U., Glaesmer, H., März, W., Stalla, G., Lehnert, H., Zeiher, A.M., Silber, S., Koch, U., Böhler, S., Pittrow, D., Ruf, G.: Cardiovascular risk factors in primary care: methods and baseline prevalence rates – DETECT program. Curr. Med. Res. Opin. 21, 619-629, 2005
196. Landmesser, U., Bahlmann, F., Müller, M., Spiekermann, S., Kirchhoff, N., Schulz, S., Manes, C., Fischer, D., de Groot, K., Fliser, D., Fauler, G., März, W., Drexler, H.: Simvastatin versus Ezetimibe: Pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111, 2356-2363, 2005
197. Löw, M., Hoffmann, M.M., Hahmann, H., März, W., Rothenbacher, D., Brenner, H.: Smoking, apolipoprotein E genotype, and early onset of coronary heart disease. Eur. J. Cardiovasc. Prev. Rehabil. 12, 268-270, 2005
198. Rothenbacher, D., Brenner, H., März, W., Koenig, W.: Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur. Heart J. 26, 1640-1646, 2005
199. Zotz, R.B., Winkelmann, B.R., Müller, C., Böhm, B.O., März, W., Scharf, R.E.: Association of polymorphisms of platelet membrane integrins alphaIIbbeta3 (HPA-1b/PlA2) and alpha2beta1 (alpha2807TT) with premature myocardial infarction. J. Thromb. Haemost. 3, 1522-1529, 2005
200. Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J.F., Ruf, G., Ritz, E.; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238-248, 2005
201. Böhm, B.O., Claudi-Böhm, S., Yildirim, S., Haenle, M.M., Hay, B., Mason, R.A., Steinbach, G., Koenig, W., Kern, P., März, W., Kratzer, W.: Prevalence of the metabolic syndrome in southwest Germany. Scand. J. Clin. Lab. Invest. 65 (Suppl. 240), 122-128, 2005
202. Khuseyinova, N., Imhof, A., Rothenbacher, D., Trischler, G., Kuelb, S., Scharnagl, H., März, W., Brenner, H., Koenig, W.: Association between Lp-PLA(2) and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis 182, 181-188, 2005
203. Pilz, S., Horejsi, R., Moller, R., Almer, G., Scharnagl, H., Stojakovic, T., Dimitrova, R., Weihrauch, G., Borkenstein, M., März, W., Schauenstein, K., Mangge, H.: Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J. Clin. Endocrinol. Metab. 90, 4792-4796, 2005
204. Meinitzer, A., Zink, M., März, W., Baumgartner, A., Halwachs-Baumann, G.: Midazolam and its metabolites in brain death diagnosis. Int. J. Clin. Pharmacol. Ther. 43, 517-526, 2005
205. Pieper, L., Wittchen, H.-U., Glaesmer, H., Klotsche, J., März, W., Stalla, G., Lehnert, H., Zeiher, A.M., Silber, S., Koch, U., Böhler, S., Pittrow, D., Ruf, G.: Kardiovaskuläre Hochrisikokonstellationen in der primärärztlichen Versorgung: DETECT Studie 2003. Bundesgesundheitsblatt 48, 1374-1382, 2005
206. Pilz, S., März, W., Weihrauch, G., Sargsyan, K., Almer, G., Nauck, M., Böhm B.O., Winkelmann, B.R., Mangge, H.: Adiponectin serum concentrations in men with coronary artery disease: The LUdwigshafen RIsk in Cardiovascular Health (LURIC) study. Clin. Chim. Acta 364, 251-255, 2006
207. Pilz, S., Scharnagl, H., Tiran, B., Seelhorst, U., Wellnitz, B., Böhm, B.O., Schäfer, J.R., März, W.: Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. J. Clin. Endocrionol. Metab. 91, 2542–2547, 2006
208. Schneider, H.J., Saller, B., Klotsche, J., März, W., Erwa, W., Wittchen, H.-U., Stalla, G.K.: Opposite associations of age-dependent insulin-like growth factor-1 standard deviation scores with nutritional state in normal weight and obese subjects. Eur. J. Endocrinol. 154, 699-706, 2006
209. Scharnagl, H., Vogel, M., Abletshauser, C., Freisinger, F., Stojakovic, T., März, W.: Efficacy and Safety of Fluvastatin-Extended Release in Hypercholesterolemic Patients: Morning Administration Is Equivalent to Evening Administration. Cardiology 106, 241-248, 2006
210. Löw, M., Hoffmann, M.M., Hahmann, H., März, W., Brenner, H., Rothenbacher, D.: Genotype combinations of plasminogen activator inhibitor-1 and angiotensin-converting enzyme genes and risk for early onset of coronary heart disease. Eur. J. Cardiovasc. Prev. Rehabil. 13, 449-456, 2006
211. Stettin, M., Halwachs-Baumann, G., Genser, B., Frühwirth, F., März, W. Khoschsorur, G.A.: Determination of cyclosporine A in whole blood: Comparison of a chromatographic method with three different immunological methods. Talanta 69, 1100-1105, 2006
212. Meisner, F., Walcher, D., Gizard, F., Kapfer, X., Huber, R., Noak, A., Sunder-Plassmann, L., Bach, H., Haug, C., Bachem, M., Stojakovic, T., März, W., Hombach, V., Koenig, W., Staels, B., Marx, N.: Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients. Data from a randomized, placebo-controlled trial. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 845-850
213. Meinitzer, A., März, W.M., Mangge, H., Halwachs-Baumann. G.: More reliable brain death diagnosis with chromatographic analysis of midazolam, diazepam, thiopentone and active metabolites. J. Anal. Toxicol. 30, 196-201, 2006
214. Trummer, O., Köppel, H., Wascher, T.C., Grünbacher, G., Gutjahr, M., Stanger, O., Ramschak-Schwarzer, S., Böhm, B.O., Winkelmann, B.R., März, W., Renner, W.: The serotonin transporter gene polymorphism is not associated with smoking behavior. Pharmacogenomics J. 6, 397-400, 2006
215. Genser, B., März, W.: Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. Clin. Res. Cardiol. 95, 393-404, 2006
216. Grammer, T.B., Renner, W., von Karger, S., Böhm, B.O., Winkelmann B.R., März, W.: The angiotensin-I converting enzyme I/D polymorphism is not associated with type 2 diabetes in individuals undergoing coronary angiography. (The Ludwigshafen Risk and Cardiovascular Health Study). Mol. Genet. Metab. 88, 378-388, 2006
217. Yazdani-Biuki, B., Brickmann, K., Wohlfahrt, K., Mueller, T., März, W., Renner, W., Gutjahr, M., Langsenlehner, U., Krippl, P., Wascher, T.C., Paulweber, B., Graninger, W., Brezinschek, H.P.: The MHC2TA -168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients. Arthritis Res. Ther. 8, R97, 2006
218. Pittrow, D., Stalla, G.K., Zeiher, A.M., Silber, S., März, W., Pieper, L., Klotsche, J., Glaesmer, H., Ruf, G., Schneider, J., Lehnert, H., Böhler, S., Koch, U., Wittchen, H.U.: Prävalenz, medikamentöse Behandlung und Einstellung des Diabetes mellitus in der Hausarztpraxis. Med. Klin. 101, 635-644, 2006
219. Pilz, S., Mangge, H., Wellnitz, B., Seelhorst, U., Winkelmann, B.R., Tiran, B., Böhm, B.O., März, W.: Adiponectin and mortality in patients undergoing coronary angiography. J. Clin. Endocrinol. Metab. 91, 4277-4286, 2006
220. Ruef, J., März, W., Winkelmann, B.R.: Markers for endothelial dysfunction, but not markers for oxidative stress correlate with classical risk factors and the severity of coronary artery disease. (A subgroup analysis from the Ludwigshafen Risk and Cardiovascular Health Study). Scand. Cardiovasc. J. 40, 274-279, 2006
221. Putz-Bankuti, C., Datz, C., März, W., Lackner, C., Stauber, R.E., Trauner, M., Toplak, H., Stojakovic, T., Krejs, G.J.: Clinical-Pathological Conference Series from the Medical University of Graz : Case No. 131: Elevated transaminases in a 30-year-old male. Wien Klin. Wochenschr. 118, 769-775, 2006
222. Böhler, S., Scharnagl, H., Freisinger, F., Stojakovic, T., Glaesmer, H., Klotsche, J., Pieper, L., Pittrow, D., Kirch, W., Schneider, H., Stalla, G.K., Lehnert, H., Zeiher, A.M., Silber, S., Koch, U., Ruf, G., März, W., Wittchen, H.U. Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis 190, 397-407, 2007
223. Fauler, G., Abletshauser, C., Erwa, W., Löser, R., Witschital, K., März, W. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics. Int. J. Clin. Pharmacol. Ther. 45, 328-334, 2007
224. Grünbacher, G., Weger, W., Marx-Neuhold, E., Pilger, E., Köppel, H., Wascher, T., März, W., Renner W. The fibrinogen gamma (FGG) 10034C>T polymorphism is associated with venous thrombosis. Thromb. Res. 121, 33-36, 2007
225. Hoffmann, M.M., Bugert, P., Seelhorst, U., Wellnitz, B., Winkelmann, B.R., Böhm, B.O., März, W. The -50G>T polymorphism in the promoter of the CYP2J2 gene in coronary heart disease: the Ludwigshafen Risk and Cardiovascular Health study. Clin. Chem. 53, 539-540, 2007
226. Krane, V., Krieter, D.H., Olschewski, M., März, W., Mann, J.F., Ritz, E., Wanner, C. Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am. J. Kidney Dis. 49, 267-275, 2007
227. März, W., Seelhorst, U., Wellnitz, B., Tiran, B., Obermayer-Pietsch, B., Renner, W., Böhm, B.O., Ritz, E., Hoffmann, M.M. Alanine to serine polymorphism at position 986 of the calcium-sensing receptor associated with coronary heart disease, myocardial infarction, all-cause, and cardiovascular mortality. J. Clin. Endocrinol. Metab. 92, 2363-2369, 2007
228. März, W., Tiran, B., Seelhorst, U., Wellnitz, B., Bauersachs, J., Winkelmann, B.R., Böhm, B.O. N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. Clin. Chem. 53, 1075-1083, 2007
229. Mayer, C., Gruber, H.J., Landl, E.M., Pailer, S., Scharnagl, H., Truschnig-Wilders, M., März, W. Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int. J. Clin. Pharmacol. Ther. 45, 319-327, 2007
230. Meinitzer, A., Puchinger, M., Winklhofer-Roob, B.M., Rock, E., Ribalta, J., Roob, J.M., Sundl, I., Halwachs-Baumann, G., März, W. Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clin. Chim. Acta 384, 141-148, 2007
231. Meinitzer, A., Seelhorst, U., Wellnitz, B., Halwachs-Baumann, G., Böhm, B.O., Winkelmann, B.R., März, W. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin. Chem. 53, 273-283, 2007
232. Pilz, S., Scharnagl, H., Tiran, B., Wellnitz, B., Seelhorst, U., Böhm, B.O., März, W. Elevated plasma free fatty acids predict sudden cardiac death: a 6.85-year follow-up of 3315 patients after coronary angiography. Eur. Heart J. 28, 2763-2769, 2007
233. Pilz, S., Weihrauch, G., Seelhorst, U., Wellnitz, B., Winkelmann, B.R., Böhm, B.O., März W. Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin. Endocrinol. 66, 380-386, 2007
234. Renner, W., Hoffmann, M.M., Grünbacher, G., Winkelmann, B.R., Böhm, B.O., März, W. G-protein beta3 subunit (GNB3) gene polymorphisms and cardiovascular disease: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Atherosclerosis 192, 108-112, 2007
235. Schäfer, C., Parlesak, A., Eckoldt, J., Bode, C., Bode, J.C., März, W., Winkler, K. Beyond HDL-cholesterol increase: phospholipid enrichment and shift from HDL3 to HDL2 in alcohol consumers. J. Lipid Res. 48, 1550-1558, 2007
236. Scharnagl, H., Stojakovic, T., Winkler, K., Rosinger, S., März, W., Böhm, B.O. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 115, 372-375, 2007
237. Schneider, H.J., Glaesmer, H., Klotsche, J., Böhler, S., Lehnert, H., Zeiher, A.M., März, W., Pittrow, D., Stalla, G.K., Wittchen, H.U. Accuracy of anthropometric indicators of obesity to predict cardiovascular risk. J Clin. Endocrinol. Metab. 92, 589-594, 2007
238. Schwab, K.O., Dörfer, J., Krebs, A., Krebs, K., Schorb, E., Hallermann, K., Superti-Furga, A., Zieger, B., März, W., Schmidt-Trucksass, A., Winkler, K. Early atherosclerosis in childhood type 1 diabetes: role of raised systolic blood pressure in the absence of dyslipidaemia. Eur. J. Pediatrics 166, 541-548, 2007
239. Stojakovic, T., Putz-Bankuti, C., Fauler, G., Scharnagl, H., Wagner, M., Stadlbauer, V., Gurakuqi, G., Stauber, R.E., März, W., Trauner. M. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 46, 776-784, 2007
240. Stojakovic, T., Scharnagl, H., März, W., Winkelmann, B.R., Böhm, B.O., Schmut, O. Low density lipoprotein triglycerides and lipoprotein(a) are risk factors for retinal vascular occlusion. Clin. Chim Acta 382, 77-81, 2007
241. Wegscheider, B.J., Weger, M., Renner, W., Steinbrugger, I., März, W., Mossbock, G., Temmel, W., El-Shabrawi, Y., Schmut, O., Jahrbacher, R., Haas, A. Association of complement factor H Y402H gene polymorphism with different subtypes of exudative age-related macular degeneration. Ophthalmology 114, 738-742, 2007
242. Winkler, K., Hoffmann, M.M., Winkelmann, B.R., Friedrich, I., Schafer, G., Seelhorst, U., Wellnitz, B., Wieland, H., Böhm, B.O., März, W. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen Risk and Cardiovascular Health study). Clin. Chem. 53, 1440-1447, 2007
243. Bach, J., Endler, G., Winkelmann, B.R., Böhm, B.O., März, W., Mannhalter, C., Hellstern, P. Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. J Thromb. Haemost. 6, 291-296, 2008
244. Dobnig, H., Pilz, S., Scharnagl, H., Renner, W., Seelhorst, U., Wellnitz, B., Kinkeldei, J., Böhm, B.O., Weihrauch, G., März, W. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 168, 1340-1349, 2008
245. Hoffmann, M.M., Pilz, S., Weihrauch, G., Seelhorst, U., Wellnitz, B., Winkelmann, B.R., Böhm, B.O., März, W. Effect of the resistin -420C > G polymorphism on cardiovascular disease and mortality. Clin. Endocrinol. 69, 344-345, 2008
246. Pilz, S., Dobnig, H., Fischer, J.E., Wellnitz, B., Seelhorst, U., Böhm, B.O., März, W. Low vitamin D levels predict stroke in patients referred to coronary angiography. Stroke 39, 2611-2613, 2008
247. Pilz, S., Dobnig, H., Winklhofer-Roob, B., Riedmuller, G., Fischer, J.E., Seelhorst, U., Wellnitz, B., Böhm, B.O., März, W. Low serum levels of 25-hydroxyvitamin D predict fatal cancer in patients referred to coronary angiography. Cancer Epidemiol. Biomarkers Prev. 17, 1228-1233, 2008
248. Siekmeier, R., Grammer, T. and März, W., Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function, J Cardiovasc Pharmacol Ther, 13, 279-297, 2008
249. Genser, B., Grammer, T. B., Stojakovic, T., Siekmeier, R. and März, W., Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis, Int J Clin Pharmacol Ther, 46, 497-510, 2008
250. Schneider, H.J., Klotsche, J., Saller, B., Böhler, S., Sievers, C., Pittrow, D., Ruf, G., März, W., Erwa, W., Zeiher, A.M., Silber, S., Lehnert, H., Wittchen, H.U., Stalla, G.K. Associations of age-dependent IGF-I SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6773 primary care patients. Eur. J. Endocrinol. 158, 153-161, 2008
251. Wilders-Truschnig, M., Mangge, H., Lieners, C., Gruber ,H., Mayer, C., März, W. IgG antibodies against food antigens are correlated with inflammation and intima media thickness in obese juveniles. Exp. Clin. Endocrinol. Diabetes 116, 241-245, 2008
252. Winkler, K., Hoffmann, M.M., Seelhorst, U., Wellnitz, B., Böhm, B.O., Winkelmann, B.R., März, W., Scharnagl H. Apolipoprotein A-II is a negative risk indicator for cardiovascular and total mortality: findings from the Ludwigshafen Risk and Cardiovascular Health Study. Clin. Chem. 54, 1405-1406, 2008
253. Krane, V., Winkler, K., Drechsler, C., Lilienthal, J., März, W., Wanner C. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int. 74, 1461-1467, 2008
254. Silber, S., Jarre, F., Pittrow, D., Klotsche, J., Pieper, L., Zeiher, A. M., Wittchen, H. U., [Cardiovascular risk assessment by primary-care physicians in Germany and its lack of agreement with the Established Risk Scores (DETECT)], Med Klin (Munich), 103, 638-645, 2008
255. Meinitzer, A., Kalcher, K., Gartner, G., Halwachs-Baumann, G., März, W., Stettin, M. Drugs and brain death diagnostics: determination of drugs capable of inducing EEG zero line. Clin Chem Lab Med 46, 1732-1738, 2008
256. Böhm, B.O., Möller, P., Hogel, J., Winkelmann, B.R., Renner, W., Rosinger, S., Seelhorst, U., Wellnitz, B., März, W., Melzner, J., Brüderlein, S. Lymphocytes of type 2 diabetic women carry a high load of stable chromosomal aberrations: A novel risk factor for disease-related early death. Diabetes 57, 2950-2957, 2008
257. Gruber, H.J., Mayer, C., Meinitzer, A., Almer, G., Horejsi, R., Moller, R., Pilz, S., März, W., Gasser, R., Truschnig-Wilders, M., Mangge, H. Asymmetric Dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. Exp. Clin. Endocrinol. Diabetes 116, 520-524, 2008
258. Pilz, S., März, W., Wellnitz, B., Seelhorst, U., Fahrleitner-Pammer, A., Dimai, H.P., Böhm, B.O., Dobnig, H. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J. Clin. Endocrinol. Metab. 93, 3927-3935, 2008
259. Winkler, K., Wanner, C., Drechsler, C., Lilienthal, J., März, W., Krane, V. Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur. Heart J. 29, 2092-2099, 2008.
260. Murr, C., Winklhofer-Roob, B.M., Schroecksnadel, K., Maritschnegg, M., Mangge, H., Bohm, B. O., Winkelmann, B. R., März, W. Fuchs, D. Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease. Atherosclerosis 202, 543-549, 2009
261. Silbernagel, G., Fauler, G., Renner, W., Landl, E. M., Hoffmann, M. M., Winkelmann, B.R. Boehm, B.O., März, W. The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease. J. Lipid Res. 50, 334-341, 2009
262. Pilz, S., Dobnig, H., Winklhofer-Roob, B. M., Renner, W., Seelhorst, U., Wellnitz, B., Boehm, B.O., März, W. Low serum zinc concentrations predict mortality in patients referred to coronary angiography. Br. J. Nutr 101, 1534-1540, 2009
263. Hoffmann, M.M., Winkler, K., Renner, W., Winkelmann, B.R., Seelhorst, U., Wellnitz, U., Boehm, B.O. März, W. Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study). J Thromb Haemost 7, 41-48, 2009
264. Grammer, T. B., März, W., Renner, W., Böhm, B.O., Hoffmann, M.M. C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC study. Eur. Heart J. 30, 170-182, 2009
265. Silbernagel, G., Stefan, N., Hoffmann, M.M., Machicao-Arano, F., Machann, J., Schick, F., Winkelmann, B.R., Böhm, B.O., Häring, H.U., Fritsche, A., März W. The L162V polymorphism of the peroxisome proliferator activated receptor alpha gene (PPARA) is not associated with type 2 diabetes, BMI or body fat composition. Exp. Clin. Endocrinol. Diabetes 117,113-118, 2009
266. Stojakovic, T., Claudel, T., Putz-Bankuti, C., Fauler, G., Scharnagl, H., Wagner, M., Sourij, H., Stauber, R. E., Winkler, K., März, W., Wascher, T. C., Trauner, M. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 209, 178-183, 2010. Epub 2009 Sep 6
267. Matzhold, E. M., Trummer, O., Grünbacher, G., Zulus, B., Böhm, B. O., März, W., Renner, W. Association of polymorphisms in the chemokine receptor CX3CR1 gene with coronary artery disease. Cytokine 47, 224-227, 2009
268. Krane, V., Winkler, K., Drechsler, C., Lilienthal, J., März, W., Wanner, C. Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. Am. J. Kidney Dis. 54, 902-911, 2009
269. Abedini, S., Holme, I., März, W., Weihrauch, G., Fellstrom, B., Jardine, A., Cole, E., Maes, B., Neumayer, H. H., Gronhagen-Riska, C., Ambuhl, P., Holdaas, H. Inflammation in renal transplantation. Clin. J. Am. Soc. Nephrol. 4, 1246-1254, 2009
270. Murr, C., Meinitzer, A., Grammer, T., Schroecksnadel, K., Böhm, B. O., März, W., Fuchs, D. Association between asymmetric dimethylarginine and neopterin in patients with and without angiographic coronary artery disease. Scand J Immunol 70, 63-67, 2009
271. Karakas, M., Hoffmann, M. M., Vollmert, C., Rothenbacher, D., Meisinger, C., Winkelmann, B., Khuseyinova, N., Bohm, B. O., Illig, T., März, W., Koenig, W. Genetic variation in Fc gamma receptor IIa and risk of coronary heart disease: negative results from two large independent populations. BMC Med. Genet 10, 46, 2009
272. Drechsler, C., Krane, V., Grootendorst, D. C., Ritz, E., Winkler, K., März, W., Dekker, F., Wanner, C. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrol. Dial. Transplant 24, 3151-3157, 2009
273. Lüblinghoff, N., Winkler, K., Winkelmann, B. R., Seelhorst, U., Wellnitz, B., Boehm, B. O., März, W., Hoffmann, M. M. Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (the Ludwigshafen Risk and Cardiovascular Health study). BMC Med. Genet. 10, 36, 2009
274. Erdmann, J., Grosshennig, A., Braund, P. S., Konig, I. R., Hengstenberg, C., Hall, A. S., Linsel-Nitschke, P., Kathiresan, S., Wright, B., Tregouet, D. A., Cambien, F., Bruse, P., Aherrahrou, Z., Wagner, A. K., Stark, K., Schwartz, S. M., Salomaa, V., Elosua, R., Melander, O., Voight, B. F., O'Donnell, C. J., Peltonen, L., Siscovick, D. S., Altshuler, D., Merlini, P. A., Peyvandi, F., Bernardinelli, L., Ardissino, D., Schillert, A., Blankenberg, S., Zeller, T., Wild, P., Schwarz, D. F., Tiret, L., Perret, C., Schreiber, S., El Mokhtari, N. E., Schafer, A., März, W., Renner, W., Bugert, P., Kluter, H., Schrezenmeir, J., Rubin, D., Ball, S. G., Balmforth, A. J., Wichmann, H. E., Meitinger, T., Fischer, M., Meisinger, C., Baumert, J., Peters, A., Ouwehand, W. H., Deloukas, P., Thompson, J. R., Ziegler, A., Samani, N. J., Schunkert, H., New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat. Genet. 41, 280-282, 2009
275. Samani, N. J., Deloukas, P., Erdmann, J., Hengstenberg, C., Kuulasmaa, K., McGinnis, R., Schunkert, H., Soranzo, N., Thompson, J., Tiret, L., Ziegler, A., Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 29, 774-780, 2009
276. Drechsler, C., Krane, V., Ritz, E., März, W., Wanner, C., Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation 120, 2421-2428, 2009
277. Grammer TB, Fuchs D, Boehm BO, Winkelmann BR, Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem. 2009 Jun;55(6):1135-46
278. Grammer TB, Renner W, Hoffmann MM, Kleber M, Winkelhofer-Roob BM, Boehm BO, Maerz W. SOD3 R231G polymorphism associated with coronary artery disease and myocardial infarction. The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Free Radic Res. 2009 Jul;43(7):677-84.
279. Grandi, N. C., Breitling, L. P., Vossen, C. Y., Hahmann, H., Wusten, B., März, W., Rothenbacher, D., Brenner, H. Serum vitamin D and risk of secondary cardiovascular disease events in patients with stable coronary heart disease, Am. Heart J. 159, 1044-1051, 2010
280. Stojakovic, T., Scharnagl, H., Trauner, M., Pieske, B., Wellnitz, B., Seelhorst, U., Schilling, D., Winkelmann, B. R., Boehm, B. O., März, W. Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography-The Ludwigshafen Risk and Cardiovascular Health Study, Atherosclerosis 208, 564-571, 2010
281. Winkler, K., Hoffmann, M. M., Krane, V., März, W., Drechsler, C., Wanner, C., Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus, Atherosclerosis, 208, 197-202, 2010
282. Tomaschitz, A., Pilz, S., Ritz, E., Grammer, T., Drechsler, C., Boehm, B. O., März, W., Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system The Ludwigshafen Risk and Cardiovascular Health (LURIC) study, Clin. Chim. Acta 411, 1354-1360, 2010
283. Casas, J. P., Ninio, E., Panayiotou, A., Palmen, J., Cooper, J. A., Ricketts, S. L., Sofat, R., Nicolaides, A. N., Corsetti, J. P., Fowkes, F. G., Tzoulaki, I., Kumari, M., Brunner, E. J., Kivimaki, M., Marmot, M. G., Hoffmann, M. M., Winkler, K., März, W., Ye, S., Stirnadel, H. A., Khaw, K. T., Humphries, S. E., Sandhu, M. S., Hingorani, A. D., Talmud, P. J. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation 121, 2284-2293, 2010
284. Collaborator für: Sarwar, N., Sandhu, M. S., Ricketts, S. L., Butterworth, A. S., Di Angelantonio, E., Boekholdt, S. M., Ouwehand, W., Watkins, H., Samani, N. J., Saleheen, D., Lawlor, D., Reilly, M. P., Hingorani, A. D., Talmud, P. J., Danesh, J., Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies, Lancet 375, 1634-1639, 2010
285. Pilz, S., Tomaschitz, A., Drechsler, C., Ritz, E., Boehm, B. O., Grammer, T. B., März, W., Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur. Heart J. 31, 1591-1598, 2010.
286. Collaborator für: Thompson, A., Gao, P., Orfei, L., Watson, S., Di Angelantonio, E., Kaptoge, S., Ballantyne, C., Cannon, C. P., Criqui, M., Cushman, M., Hofman, A., Packard, C., Thompson, S. G., Collins, R., Danesh, J., Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375, 1536-1544, 2010
287. Kozian, D. H., Barthel, A., Cousin, E., Brunnhofer, R., Anderka, O., März, W., Bohm, B., Winkelmann, B., Bornstein, S. R., Schmoll, D. Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study. Horm. Metab. Res. 42, 502-506, 2010
288. Silbernagel, G., Fauler, G., Hoffmann, M. M., Lutjohann, D., Winkelmann, B. R., Boehm, B. O., März, W. The associations of cholesterol metabolism and plasma plant sterols with all-cause- and cardiovascular mortality. J Lipid Res. 51, 2384-2393, 2010
289. Schroecksnadel, K., Grammer, T. B., Boehm, B. O., März, W., Fuchs, D. Total homocysteine in patients with angiographic coronary artery disease correlates with inflammation markers. Thromb Haemost 103, 926-935, 2010
290. Kozian, D. H., Lorenz, M., März, W., Cousin, E., Mace, S., Deleuze, J. F., Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study. Thromb. Haemost. 103, 976-983, 2010
291. Tomaschitz, A., Pilz, S., Ritz, E., Meinitzer, A., Boehm, B. O., März, W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J, 31, 1237-1247, 2010
292. Stojakovic, T., de Campo, A., Scharnagl, H., Sourij, H., Schmolzer, I., Wascher, T. C., März, W., Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. Eur. J. Clin. Invest. 40, 187-194, 2010
293. Ritsch, A., Scharnagl, H., Eller, P., Tancevski, I., Duwensee, K., Demetz, E., Sandhofer, A., Boehm, B. O., Winkelmann, B. R., Patsch, J. R., März, W. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 121, 366-374, 2010
294. Kleber, M. E., Renner, W., Grammer, T. B., Linsel-Nitschke, P., Boehm, B. O., Winkelmann, B. R., Bugert, P., Hoffmann, M. M., März, W. Association of the single nucleotide polymorphism rs599839 in the vicinity of the sortilin 1 gene with LDL and triglyceride metabolism, coronary heart disease and myocardial infarction. The Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis 209, 492-497, 2010
295. Abedini, S., Meinitzer, A., Holme, I., März, W., Weihrauch, G., Fellstrom, B., Jardine, A., Holdaas, H., Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int. 77, 44-50, 2010
296. Pilz, S., Obermayer-Pietsch, B., Verduijn, M., Tomaschitz, A., Krane, V., Espe, K., Dekker, F., Brandenburg, V., März, W., Ritz, E., Wanner, C. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur. Heart J. 31, 2253-61, 2010
297. Sievers, C., Klotsche, J., Pieper, L., Schneider, H. J., März, W., Wittchen, H. U., Stalla, G. K., Mantzoros, C. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. Eur. J. Endocrinol. 163, 699-708, 2010
298. Preuss M, König IR, Thompson JR, Erdmann J, Absher D, Assimes TL, Blankenberg S, Boerwinkle E, Chen L, Cupples LA, Hall AS, Halperin E, Hengstenberg C, Holm H, Laaksonen R, Li M, März W, McPherson R, Musunuru K, Nelson CP, Burnett MS, Epstein SE, O'Donnell CJ, Quertermous T, Rader DJ, Roberts R, Schillert A, Stefansson K, Stewart AF, Thorleifsson G, Thorsteinsdottir U, Voight BF, Wells GA, Ziegler A, Kathiresan S, Reilly MP, Samani NJ, Schunkert H. Design of the Coronary Artery Disease Genome-Wide Replication and Meta-Analysis (CARDIoGRAM) Study -- A Genome-Wide Association Meta-Analysis Involving More than 22,000 Cases and 60,000 Controls. Circ Cardiovasc Genet. 2010 Oct 1;3(5):475-83. Epub Oct 5
299. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, Bouatia-Naji N, Langenberg C, Prokopenko I, Stolerman E, Sandhu MS, Heeney MM, Devaney JM, Reilly MP, Ricketts SL, Stewart AF, Voight BF, Willenborg C, Wright B, Altshuler D, Arking D, Balkau B, Barnes D, Boerwinkle E, Böhm B, Bonnefond A, Bonnycastle LL, Boomsma DI, Bornstein SR, Böttcher Y, Bumpstead S, Burnett-Miller MS, Campbell H, Cao A, Chambers J, Clark R, Collins FS, Coresh J, de Geus EJ, Dei M, Deloukas P, Döring A, Egan JM, Elosua R, Ferrucci L, Forouhi N, Fox CS, Franklin C, Franzosi MG, Gallina S, Goel A, Graessler J, Grallert H, Greinacher A, Hadley D, Hall A, Hamsten A; on behalf of Procardis Consortium, Hayward C, Heath S, Herder C, Homuth G, Hottenga JJ, Hunter-Merrill R, Illig T, Jackson AU, Jula A, Kleber M, Knouff CW, Kong A, Kooner J, Köttgen A, Kovacs P, Krohn K, Kühnel B, Kuusisto J, Laakso M, Lathrop M, Lecoeur C, Li M, Li M, Loos RJ, Luan J, Lyssenko V, Mägi R, Magnusson PK, Mälarstig A, Mangino M, Martínez-Larrad MT, März W, McArdle WL, McPherson R, Meisinger C, Meitinger T, Melander O, Mohlke KL, Mooser VE, Morken MA, Narisu N, Nathan DM, Nauck M, O'Donnell C, Oexle K, Olla N, Pankow JS, Payne F, Peden JF, Pedersen NL, Peltonen L, Perola M, Polasek O, Porcu E, Rader DJ, Rathmann W, Ripatti S, Rocheleau G, Roden M, Rudan I, Salomaa V, Saxena R, Schlessinger D, Schunkert H, Schwarz P, Seedorf U, Selvin E, Serrano-Ríos M, Shrader P, Silveira A, Siscovick D, Song K, Spector TD, Stefansson K, Steinthorsdottir V, Strachan DP, Strawbridge R, Stumvoll M, Surakka I, Swift AJ, Tanaka T, Teumer A, Thorleifsson G, Thorsteinsdottir U, Tönjes A, Usala G, Vitart V, Völzke H, Wallaschofski H, Waterworth DM, Watkins H, Wichmann HE, Wild SH, Willemsen G, Williams GH, Wilson JF, Winkelmann J, Wright AF; WTCCC, Zabena C, Zhao JH, Epstein SE, Erdmann J, Hakonarson HH, Kathiresan S, Khaw KT, Roberts R, Samani NJ, Fleming MD, Sladek R, Abecasis G, Boehnke M, Froguel P, Groop L, McCarthy MI, Kao WH, Florez JC, Uda M, Wareham NJ, Barroso I, Meigs JB.Common variants at ten genomic loci influence hemoglobin A1C levels via glycemic and non-glycemic pathways. Diabetes. 2010 Sep 21.
300. März, W., Meinitzer, A., Drechsler, C., Pilz, S. Krane, V., Kleber, M.E., Fischer, J., Winkelmann, B.R., Böhm, B.O., Ritz, E., Wanner, C. Homoarginine, cardiovascular risk, and mortality. Circulation 122, 967-75, 2010
301. Saleheen, D., Soranzo, N., Rasheed, A., Scharnagl, H., Gwiliam, R., Alexander, M., Inouye, M., Zaidi, M., Potter, S., Haycock, P., Bumpstead, S., Kaptoge, S., Angelantonio, E. D., Sarwar, N., Hunt, S. E., Sheikh, N., Shah, N., Samuel, M., Haider, S. R., Murtaza, M., Thompson, A., Gobin, R., Butterworth, A., Ahmad, U., Hakeem, A., Zaman, K. S., Kundi, A., Yaqoob, Z., Cheema, L. A., Qamar, N., Faruqui, A., Mallick, N. H., Azhar, M., Samad, A., Ishaq, M., Rasheed, S. Z., Jooma, R., Niazi, J. H., Gardezi, A. R., Memon, N. A., Ghaffar, A., Rehman, F. U., Hoffmann, M. M., Renner, W., Kleber, M., Grammer, T. B., Stephens, J., Attwood, A., Koch, K., Hussain, M., Kumar, K., Saleem, A., Daood, M. S., Gul, A. A., Abbas, S., Zafar, J., Shahid, F., Bhatti, S. M., Ali, S. S., Fahim, M., Sagoo, G., Bray, S., McGinnis, R., Dudbridge, F., Winkelmann, B. R., Bohm, B., Thompson, S., Ouwehand, W., März, W., Frossard, P., Danesh, J., Deloukas, P., Genetic Determinants of Major Blood Lipids in Pakistan Is Compared with Europeans. Circ Cardiovasc Genet 2010 Aug;3(4):348-57. Epub 2010 Jun 22.
302. Wehr, E., Pilz, S., Boehm, B. O., März, W., Obermayer-Pietsch, B. Association of vitamin D status with serum androgen levels in men. Clin Endocrinol (Oxf), 2010 Aug;73(2):243-8
303. Tomaschitz A, Maerz W, Pilz S, Ritz E, Scharnagl H, Renner W, Boehm BO, Fahrleitner-Pammer A, Weihrauch G, Dobnig H. Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J Am Coll Cardiol. 2010 May 11;55(19):2171-80.
304. Drechsler C, Pilz S, Obermayer-Pietsch B, Verduijn M, Tomaschitz A, Krane V, Espe K, Dekker F, Brandenburg V, März W, Ritz E, Wanner C. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J. 2010 Sep;31(18):2253-61.
305. Wehr E, Pilz S, Boehm BO, März W, Grammer TB, Obermayer-Pietsch B. Sex steroids and mortality in men referred for coronary angiography. Clin Endocrinol (Oxf). 2010 Nov;73(5):613-21.
306. Bakris G, Vassalotti J, Ritz E, Wanner C, Stergiou G, Molitch M, Nesto R, Kaysen GA, Sowers JR; CKD Consensus Working Group. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int. 2010 Oct;78(8):726-36.
307. Meinitzer A, Kielstein JT, Pilz S, Drechsler C, Ritz E, Boehm BO, Winkelmann BR, März W. Symmetrical and Asymmetrical Dimethylarginine as Predictors for Mortality in Patients Referred for Coronary Angiography: The Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem. 2010 Oct 29. [Epub ahead of print]
308. Haschke-Becher E, Kirchheiner J, Trummer O, Grünbacher G, Kainz A, Boehm BO, März W, Renner W. Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort. Pharmacogenomics. 2010 Oct;11(10):1359-65.
309. Schneider H, Friedrich N, Klotsche J, Schipf S, Nauck M, Volzke H, Sievers C, Pieper L, März W, Wittchen HU, Stalla GK, Wallaschofski H. Prediction of incident diabetes mellitus by baseline insulin-like growth factor-I levels. Eur J Endocrinol. 2010 Nov 8. [Epub ahead of print]
310. Kleber ME, Grammer TB, Renner W, März W. Effect of the rs2259816 polymorphism in the HNF1A gene on circulating levels of c-reactive protein and coronary artery disease (the ludwigshafen risk and cardiovascular health study). BMC Med Genet. 2010 Nov 9;11:157.
311. Pilz S, Tomaschitz A, März W. Vitamin d deficiency and stroke: time to act! Am J Cardiol. 2010 Dec 1;106(11):1674. Comment
312. Marzi C, Albrecht E, Hysi PG, Lagou V, Waldenberger M, Tönjes A, Prokopenko I, Heim K, Blackburn H, Ried JS, Kleber ME, Mangino M, Thorand B, Peters A, Hammond CJ, Grallert H, Boehm BO, Kovacs P, Geistlinger L, Prokisch H, Winkelmann BR, Spector TD, Wichmann HE, Stumvoll M, Soranzo N, März W, Koenig W, Illig T, Gieger C. Genome-Wide Association Study Identifies Two Novel Regions at 11p15.5-p13 and 1p31 with Major Impact on Acute-Phase Serum Amyloid A. PLoS Genet. 2010 Nov 18;6(11)
WISSENSCHAFTLICHE ÜBERSICHTSARBEITEN
1. Groß, W., März, W.: Aspekte zum qualitativen und quantitativen Nachweis humaner Apolipoproteine. Funkt. Biol. Med. 2, 234-240, 1983
2. Groß, W., März, W.: Immunoelectrophoretic techniques in protein analysis and quantitation. International Biotechnology Laboratory 6, 6-19, 1988
3. März, W., Wanner, C., Wieland, H.: Pharmakotherapie der Dyslipoproteinämien. Deutsche Apotheker Zeitung 135, 17-34, 1994
4. März, W., Wanner, C., Wieland, H.: Pharmakotherapie der Dyslipoproteinämien. In: Mutschler, E., Moser, U., Schäfer-Korting, M. (Hrsg.) Aktuelle Pharmakologie 35, pp. 315-325, 1994
5. März, W., Wanner, C., Wieland, H.: Dyslipoproteinämien und Lipidsenker. Aktuelle Pharmakologie. Ausbildungsreihe für Krankenhausapotheker 35, 315-324, 1995
6. März, W., Wanner, C., Wieland, H.: Dyslipoproteinämien und Lipidsenker. Deutsche Apotheker Zeitung 135, 943-960, 1995
7. Scharnagl, H., März, W., Wieland, H.: Lifibrol: first member of a new class of lipid-lowering drugs? Exp. Opin. Invest. Drugs 6, 583-591, 1997 (Mitarbeit am Manuskript)
8. Wheal, H.V., Chen, Y., Mitchell, J., Schachner, M., März, W., Wieland, H., van Rossum, D., Kirsch, J.: Molecular mechanisms that underlie structural and functional changes at the postsynaptic membrane during synaptic plasticity. Prog. Neurobiol. 55, 611-640, 1998
9. Groß, W., März, W.: Application of electrophoretic techniques to the diagnosis of disorders of lipoprotein metabolism. Examples at the levels of lipoproteins and apolipoproteins. Anal. Chim. Acta 383, 169-184, 1999
10. März, W., Wieland, H.: HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering? Herz 25, 117-125, 2000
11. März, W., Nauck, M., Wieland, H.: The molecular mechanisms of inherited thrombophilia. Intensivmed. 37 (Suppl. 1) I/1-I/15, 2000
12. März, W., Nauck, M., Wieland, H.: The molecular mechanisms of inherited thrombophilia. Molekulare Mechanismen der angeborenen Thrombophilie. Z. Kardiol. 89, 575-586, 2000
13. Hoffmann, M.M., Winkelmann, B.R., Wieland, H., März, W.: The significance of genetic polymorphisms in modulating the response to lipid- lowering drugs. Pharmacogenomics 2, 107-121, 2001
14. Nauck, M.S., März, W., Nauck, M.A., Wieland, H.: Moderne molekulabiologische Thrombophiliediagnostik: Die Genotypisierung der Faktor-V-Leiden- und der Prothrombin-G20210A-Mutation mit dem LightCycler. Hämostaseologie 21, 37-43, 2001
15. März, W., von Eckardstein, A.: Laboratoriumsdiagnostik bei Fettstoffwechselstörungen. Laboratory diagnostics of lipid disorders. J. Lab. Med. 25, 433-448, 2001
16. März, W., Winkelmann, B.R.: Akutes Koronarsyndrom: Früher Einsatz von Statinen. Cardiovasc 2 (1), 68-69, 2002
17. März, W., Winkelmann, B.R.: HMG-CoA reductase inhibition in the treatment of atherosclerosis: effects beyond lipid lowering. J. Kardiol. 9, 284-294, 2002
18. Ballantyne, C.M., Corsini, A., Davidson, M.H., Holdaas, H., Jacobson, T.A., Leitersdorf, E., März, W., Reckless, J.P.D., Stein E.A.: Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. 163, 553-564, 2003
19. März, W., Koenig, W.: HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering? J. Cardiovasc. Risk 10, 69-79, 2003
20. März, W., Jacob, S.: Verbesserung des Lipidprofils: Ein entscheidender Faktor für die Prognose des Typ-2-Diabetikers, Arzt & Praxis 57, 396-404, 2003
21. Truschnig-Wilders, M., Böhm, B.O., März, W.: Laboratoriumsdiagnostik bei Diabetes mellitus. J. Lab. Med. 28, 334-345, 2004
22. Mangge, H., Hubmann, H., Pilz, S., März, W.: Inflammatorische Biomarker und Atherosklerose. J. Lab. Med. 28, 346-353, 2004
23. Döser, S., März, W., Reinecke, M.F., Ringleb, P., Schultz, A., Schwandt, P., Becker, H.J., Bönner, G., Buerke, M., Diener, H.C., Gohlke, H., Keil, U., Ringelstein, E.B., Steinmetz, A., Gladisch, R., Wehling, M.: Empfehlungen zur Statintherapie im Alter. Daten und Konsensus. Der Internist 45, 1053-1062, 2004
24. Böhler, S., Glaesmer, H., Pittrow, D., Lehnert, H., Stalla, G.K., Zeiher, A.M., März, W., Silber, S., Wehling, M., Ruf, G., Reinecke, A., Wittchen, H.-U.: Diabetes and cardiovascular risk evaluation and management in primary care: Progress and unresolved issues. Rationale for a nationwide primary care project in Germany. Exp. Clin. Endocrinol. Diabetes 112, 157-170, 2004
25. März, W.: Behandlung der diabetischen Dyslipidämie. Stellenwert der Behandlung mit HMG-COA-Reduktasehemmern. pro-CME, Thieme Verlag, Stuttgart 2004 (Zeitschriftenbeilage)
26. Mangge, H., Hubmann, H., Pilz, S., Schauenstein, K., Renner, W., März, W.: Beyond cholesterol - inflammatory cytokines, the key mediators in atherosclerosis. Clin. Chem. Lab. Med. 42, 467-474, 2004
27. Stojakovic, T., Scharnagl, H., März, W.: ApoE: Crossroads between Alzheimer’s disease and atherosclerosis. Sem. Vasc. Med. 4, 279-285, 2004
28. Assmann, G., Corsini, A., Davignon, J., Grundy, S.M., Libby, P., März, W., Mason, R.P., Nissen, S.E., Pedersen, T.R., Ridker, P.M., Riesen, W., Schaefer, E.J., Waters, D.: Cholesterol-lowering with statins: Are they all the same? Drugs of Today 40, 555-561, 2004
29. Scharnagl, H., März, W.: New lipid-lowering agents acting on LDL receptors. Curr. Top. Med. Chem. 5, 233-242, 2005
30. März, W.: Auch bei niedrigem LDL-Cholesterin aggressiv therapieren – Aktueller Stellenwert der Statintherapie beim akuten Koronarsyndrom. Klinikarzt 34, 108-112, 2005
31. März, W.: Lowering LDL-cholesterol: Where is the end of the journey? Heart Drug 5, 39-55, 2005
32. Schwab, K.O., Schmidt-Trucksäss, A., Krebs, A., Krebs, K., März, W., Dörfer, J., Brandis, M., Sutor, A.: Risikofaktoren für eine Atherosklerose bei Kindern und Jugendlichen mit Typ-1-Diabetes mellitus. Pädiatr. Prax. 273-283, 66, 2005
33. März, W.: Konsequenzen aus der „A to Z“-Studie. Cholesterin beim akuten Koronarsyndrom früh und aggressiv senken? Herz 30, 78-80, 2005
34. Pilz, S., Mangge, H., Obermayer-Pietsch, B., März, W.: Visfatin/pre-B-cell colony-enhacing factor (PBEF): A protein with various suggested functions. J. Endocrinol. Invest. 30, 138-144, 2006
35. Siekmeier, R., Steffen, C., März, W.: Können Antioxidanzien Atherosklerose verhindern? Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 49, 1034-1049, 2006
36. März, W. u.a.: Modernes Lipidmanagement – Stellenwert von Rosuvastatin aus kardiologischer Sicht. Experten Statement. Internationale Zeitschrift für ärztliche Fortbildung, 1, 2007
37. März, W., Grammer, T.B.: [Lowering LDL cholesterol: How much is enough?] Der Internist 48, 319-326, 2007
38. Pfützner, A., Forst, T., März, W., Jacob, S.: Evidenzbasierte Medizin. Theoretische Grundlagen und aktueller Missbrauch zur Kosteneinsparung im Gesundheitswesen. Der Internist 48, 426-435, 2007
39. März W. [Discussion of the safety of lipid therapy. Low LDL-high cancer risk?. MMW Fortschritte der Medizin 149, 19, 2007
40. Siekmeier R, Steffen C, März W. Role of oxidants and antioxidants in atherosclerosis: results of in vitro and in vivo investigations. J. Cadiovasc. Pharmacol. Ther. 12, 265-282, 2007
41. Pilz S, März W. Free fatty acids as a cardiovascular risk factor. Clin Chem Lab Med 46, 429-434, 2007
42. Siekmeier, R., Grammer, T., März, W. Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function. J. Cadiovasc. Pharmacol. Ther. 13, 279-297, 2008
43. Schernthaner, G., Forst, T., Gulba, D., Haberbosch, W., Hanefeld, M., Linss, G., März, W., Mehnert, H., Rosak, C., Schnell, O., Seufert, J., Tschope, D., Erdmann, E., [Challenge in diabetes therapy: effects of glitazones beyond blood glucose control], Dtsch Med Wochenschr, 134, 949-954, 2009
44. Pilz, S., Tomaschitz, A., Drechsler, C., Dekker, J. M., März, W. Vitamin D deficiency and myocardial diseases, Mol Nutr Food Res, 2010 Aug;54(8):1103-13
45. Pliz, S., Tomaschitz, A., Drechsler, C., Zittermann, A., Dekker, J.M., März, W. Vitamin D supplementation: A promising approach for the prevention and treatmet of strokes. Curr Drug Targets. 2010 Aug 27. [Epub ahead of print]
46. Pilz, S. Tomaschitz, A., März, W., Cavalier, E., Ritz, E. Aldosterone and parathyroid hormone : a complex and clinically relevant relationsip. Calcif. Tissue Int. 87, 373-374, 2010
47. März W, Grammer TB. C-reactive protein and coronary heart disease: quo vadis? MMW Fortschr Med. 2009 Oct;151 Suppl 3:127-32.
48. Klose G, März W, Grammer TB, Nitschmann S. Rosuvastatin for primary prevention of vascular events : JUPITER trial (Justification for the Use of statins in Prevention: an Intervention Trial Evaluation Rosuvastatin). Internist (Berl). 2010 Jan;51(1):103-106.
BUCHBEITRÄGE UND MONOGRAPHIEN 1. März, W., Romberg, G., Gahn, G., Groß, W., Kuhl, H., Taubert, H.-D.: Effect of oral contraceptives upon
serum lipoprotein pattern in healthy women. In: Rolland, R., Harrison, R.F., Bonnar, J., Thompson, W. (Eds.): Advanvces in Fertility Control and the Treatment of Sterility, pp. 99-105, MTP Press Ltd., Lancaster, Boston, The Hague, Dordrecht 1983
2. Kuhl, H., März, W., Groß, W., Gahn, G., Romberg, G., Taubert, H.-D.: Die Wirkung zweier niedrigdosierter oraler Kontrazeptiva auf die Serumlipoproteine. In: Beller, F.K., Giesing, M., Graeff, H. (Hrsg.): Hormonale Kontrazeption und Herzkreislauf, pp. 49-59, SMV Verlagsgesellschaft mbH, Gräfelfing 1987
3. Wieland, H., März, W., Nauck, M.: Diagnostics of Lipids and Lipoproteins. In: Lanzer, P., Rösch, J. (Eds.): Vascular Diagnostics, pp. 33-73, Springer-Verlag, Berlin, Heidelberg 1994
4. Kostner, G.M., März, W.: Zusammensetzung und Stoffwechsel der Lipoproteine. In: Schwandt, P., Richter, W.O. (Hrsg.): Handbuch der Fettstoffwechselstörungen, pp. 3-47, Schattauer, Stuttgart, New York 1995
5. Wieland, H., März, W.: Lipidstoffwechselstörungen. In: Mutschler, E., Platt, D. (Hrsg.): Pharmakotherapie im Alter, pp. 246-267, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 1999
6. März, W., Wieland, H.: Lipidsenkende Therapie in der primären und sekundären Prophylaxe der koronaren Herzkrankheit. In: Griebenow, R., Gülker, H., Dominiak, P., Piper, H. (Hrsg.): Autonomes Nervensystem und koronare Herzkrankheit. Cardiovascularia (Novartis), pp. 330-367, 2000
7. Winkelmann, B.R., Nauck, M., Scheffold, T., März, W.: Molekularbiologische Methoden und Genanalysen bei kardialen Erkrankungen. In: Kaltenbach, M. (Hrsg.): Kardiologie kompakt, pp. 79-113, Steinkopff Verlag, 2. Aufl., Darmstadt 2000
8. Winkelmann, B.R., Nauck, M., Scheffold, T., März, W.: Glossar genetischer und molekularbiologischer Begriffe [Kapitel 20]. In: Kaltenbach M (Hrsg.): Kardiologie-Information, pp. 357-361, Steinkopff Verlag, 2. Aufl., Darmstadt 2000
9. März, W., Nauck, M.A., Wieland, H.: The molecular mechanisms of inherited thrombophilia. In: Geibel, A., Just, H., Kasper, W., Konstantinidis, S. (Hrsg.): Acute pulomary embolism - a challenge for hemostasiology. New concepts in Cardiovascular Diagnosis and Treatment, pp. 1-20, Steinkopff Verlag, Darmstadt 2000
10. März, W., Nauck, M.S., Fisher, E., Hoffmann, M.M., Wieland, H.: The molecular mechanisms of inherited hypercholesterolemia. In: Zehender, M., Breithardt, G., Just, H. (Hrsg.): From molecule to men - molecular basis of congenital cardiovascular disorders, pp. 151-169, Steinkopff Verlag, Darmstadt 2000
11. März, W., Winkler, K., Wieland, H.: Therapie des Diabetes mellitus. In: von Bruchhausen, F., Lemmer, B. (Hrsg.): Arzneimitteltherapie für ältere Menschen, Springer Verlag, Heidelberg 2000
12. März, W., Wieland, H.: Lipidsenkende Therapie. In: von Bruchhausen, F., Lemmer, B. (Hrsg.): Arzneimitteltherapie für ältere Menschen, Springer Verlag, Heidelberg 2000
13. Nauck, M.S., Gierens, H., Nauck, M.A., März, W., Wieland, H.: Rapid, homogeneous genotyping of human platelet antigen 1 by fluorescence resonance energy transfer and probe melting curves. In: Meuerer, S., Wittwer, C., Nakagawa, K. (Hrsg.): Rapid Cycle Real-Time PCR – Methods and Applications, pp. 273-279, Springer-Verlag, Berlin 2001
14. Kostner, G.M., März, W.: Zusammensetzung und Stoffwechsel der Lipoproteine. In: Schwandt, P., Richter, W.O. (Hrsg.): Handbuch der Fettstoffwechselstörungen, pp. 1-57, 2. Aufl., Schattauer, Stuttgart, New York, 2001
15. Nauck, M., März, W., Wieland, H.: Rapid detection of missense mutations in the prostatic steroid 5α-reductase gene using real-time fluorescence PCR and melting curve analysis. In: Dietmaier, W., Wittwer, C., Sivasubramanian, N. (Eds.): Rapid Cycler Real-Time PCR – Methods and Applications; Genetics and Oncology, pp. 129-135, Springer Verlag, Berlin 2002
16. Winkelmann, B.R., Nauck, M.S., Hoffmann, M.M., März, W.: Pharmacogenomics and complex cardiovascular diseases – clinical studies in candidate genes [chapter 12]. In: Licinio, J., Wong, M.-L. (Eds.): Pharmacogenomics: The Search for Individualized Therapeutics, pp. 251-266, Wiley-VCH, New York 2002
17. Hoffmann, M.M., Winkelmann, B.R., Wieland, H., März, W.: Pharmacogenomics of lipid lowering agents [chapter 13]. In: Licinio, J., Wong, M.-L. (Eds.): Pharmacogenomics: The Search for Individualized Therapeutics, pp. 267-281, Wiley-VCH, New York 2002
18. Winkelmann, B.R., Hoffmann, M.M., März, W.: Glossary of molecular genetic terminology [chapter 27]. In: Licinio, J., Wong, M.-L. (Eds.): Pharmacogenomics: The Search for Individualized Therapeutics, pp. 531-538, Wiley-VCH, New York 2002
19. Winkelmann, B.R., März, W.: An epidemiological perspective. Society, environment, risk factors, and genetics. [chapter 3]. In: Théroux, P.: Acute coronary syndromes – a companion to Braunwald’s Heart Disease, pp. 15-48, Saunders, New York 2003
20. Winkelmann, B.R., Hoffmann, M.M., März, W.: Lipid-lowering responses modified by genetic variation. In: Wilkins M.R. (ed.): Cardiovascular Pharmacogenetics. Handbook of Experimental Pharmacology, Vol. 160, pp. 108-147, Springer-Verlag, Heidelberg 2004
21. Dryden, W.A., Kreuzer, J., Künzel, D., März, W., Sturm, D., Wahle, K.: Fettstoffwechselstörungen in der Hausarztpraxis. Wer? Was? Wann? Wie? Ein Leitfaden des Deutschen Hausärzteverbandes, 2004 (Broschüre)
22. Scharnagl, H., Stojakovic, T., März, W.: Lipidstoffwechsel. In: Sinha, P. (Hrsg.): Laborbefunde und ihre klinischen Interpretationen. Methoden der Laboruntersuchung, Diagnosestrategien, Differentialdiagnosen, chapter 3/3.3-4/3.3.9, Spitta Verlag, Balingen 2005
23. Krebs, K., März, W.: Lipidsprechstunde. Praxisrelevante Fettstoffwechselstörungen und ihre Folgen. Band 1: Grundlagen, Georg Thieme Verlag, 90 S., Stuttgart/New York 2006
24. Kostner, G.M., Scharnagl, H., Kostner, K., März, W.: Zusammensetzung und Stoffwechsel der Lipoproteine. In: Schwandt, P., Parhofer, G., Handbuch der Fettstoffwechselstörungen, 3. Aufl., Schattauer, Stuttgart, New York 2007, pp. 1-65
25. Scharnagl H, Stojakovic T, März W. Biomarker in Forschung und Diagnostik. In: Schmitz G, Endres S, Götte D (Hrsg.). Biomarker: Bedeutung für medizinischen Fortschritt und Nutzbewertung, Schattauer, Stuttgart, Germany, 2008, S. 15-37
26. Scharnagl, H., März, W.: Familial Ligand-Defective Apolipoprotein B-100 (FDB). In: Lang F (Editor). Encyclopedia of Molecular Mechanisms of Disease, Springer Verlag, Berlin Heidelberg, Germany, 2009, Vol. 2, S.1175-1176
27. Hoffmann, M.M., März, W.: Apolipoprotein C-II Deficiency. In: Lang F (Editor). Encyclopedia of Molecular Mechanisms of Disease, Springer Verlag,, Berlin Heidelberg, Germany, 2009, Vol. 1, S.132-133
28. Scharnagl, H., März, W.: Abetalipoproteinemia (ABL). In: Lang F (Editor). Encyclopedia of Molecular Mechanisms of Disease, Springer Verlag,, Berlin Heidelberg, Germany, 2009, Vol. 1, S.1-2
29. Scharnagl, H., März, W.: Chylomicron Retention Disease (CMRD). In: Lang F (Editor). Encyclopedia of Molecular Mechanisms of Disease, Springer Verlag,, Berlin Heidelberg, Germany, 2009, Vol. 1, S.359-360
30. Scharnagl, H., März, W.: Familial hypobetalipoproteinemia (FHBL). In: Lang F (Editor). Encyclopedia of Molecular Mechanisms of Disease, Springer Verlag,, Berlin Heidelberg, Germany, 2009, Vol. 2, S-962
31. Scharnagl H, Stojakovic T, März W. New lipid-lowering agents acting on LDL receptors. In: Reitz AB, Choudhary MI, Attar-ur-Raman (Eds.). Frontiers in Medicinal Chemistry, Vol. 4, 2009, S.642-660
